

VII. Referencias

- Abdel-Baki A, Lesage A, Nicole L, Cossette M, Salvat E, Lalonde P. Schizophrenia, an illness with bad outcome: myth or reality? *Can J Psychiatry* 2011;56:92-101.
- Abdul-Rahman MF, Qiu A, Woon PS, Kuswanto C, Collinson SL, Sim K. Arcuate fasciculus abnormalities and their relationship with psychotic symptoms in schizophrenia. *PLoS One* 2012;7:e29315.
- Abraham KR, Kulhara P. The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. *Br J Psychiatry* 1987;151:152-155.
- Abrams R, Swartz, CM. Electroconvulsive therapy apparatus and method for automatic monitoring of patient seizures. US. Patent 1989;4878898.
- Abrams R, Colin R. Aplicación clínica del monitoreo convulsivo electroencefalográfico durante Terapia Electroconvulsiva. *Salud Mental* 1995;18(3):235-249.
- Adams CE, Coutinho E, Duggan L, Gilbody S, Leucht S, Wahlbeck K. Cochrane schizophrenia group. *Cochrane2 Database Syst Rev* 2003 (4):CDD51334.
- Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. *Br J Psychiatry* 2001;179:290-299.
- Addington AM, Gornick M, Duckworth J. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. *Mol Psychiatry* 2005;10:581-588.
- Addington AM, Rapoport JL. The genetics of childhood-onset schizophrenia: When madness strikes the pubescent. *Curr Psychiatry Rep* 2009;11:156-161.
- Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. *Schizophr Res* 1992;6:201-208.
- Addington DJ, Patten S. Depression in people with first-episode schizophrenia. *Br J Psychiatry* 1998;172:90-92.
- Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO et al. At clinical high risk for psychosis: outcome for nonconverters. *Am J Psychiatry* 2011;168:800-805.
- Addington J, Leriger E, Addington D. Symptom outcome 1 year after admission to an early psychosis program. *Can J Psychiatry* 2003;48:204-207.
- Adler CM, McDonough-Ryan P, Sax KW, Holland SK, Arndt S, Strakowski SM. MRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder. *J Psychiatr Res* 2000;34:317-324.
- Agid O, Seeman P, Kapur A. The "delayed onset" of antipsychotic action - an idea whose time has come and gone. *J Psychiatry Neurosci* 2006;31:93-100.
- Agid Y, Buzsáki G, Diamond DM, Frackowiak R, Giedd J, Girault JA et al. How can drug discovery for psychiatric disorders be improved? *Nat Rev Drug Discov* 2007;6:189-201.
- Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles. *Drug Saf* 2006;29:587-598.
- Alaghband-Rad J, McKenna K, Gordon CT, Albus KE, Hamburger SD, Rumsey JM. Childhood-onset schizophrenia: The severity of premorbid course. *J Am Acad Child Adolesc Psychiatry* 1995;34:1273-1283.
- Albanese MJ, Khantzian EJ, Murphy SL. Decreased substance use in chronically psychotic patients treatment with clozapine. *Am J Psychiatry* 1994;151:780-781.
- Aleman A, Kahn RS. Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? *Prog Neurobiol* 2005;77:283-298.
- Alevizos B, Lykouras L, Zervas IM, Christodoulou GN. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. *J Clin Psychopharmacol* 2002;22:461-467.
- Alexander MP, Naeser MA. Cortical-subcortical differences in aphasia. *Res Publ Assoc Res Nerv Ment Dis*. 1988;66:215-228.
- Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. *J Clin Psychiatry* 2001;62:22-31.
- Alphs L, Gopal S, Karcher K, Kent J, Sliwa JK, Kushner S et al. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. *Curr Drug Saf* 2011;6:43-45.
- Alvarez JM, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. A systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. *Schizophr Bull* 2011;37:610-630.
- Alvarez PA, Pahissa J. QT Alterations in psychopharmacology: proven candidates and suspects. *Curr Drug Saf* 2010;5:97-104.
- Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaff JA. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. *N Engl J Med* 1993;329:162-167.
- Amador XF, Strauss DH, Yale S, Gorman JM, Endicott J. The assessment of insight in psychosis. *Am J Psychiatry* 1993;150:873-879.
- Amaresha AC, Venkatasubramanian G. Expressed emotion in schizophrenia: an overview. *Indian J Psychol Med* 2012;34:12-20.
- American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of child and adolescent schizophrenia. *J Am Acad Child Adolesc Psychiatry* 2001;40:4S-23S.
- American Psychiatric Association practice guidelines for the assessment and treatment of patients with suicidal behaviors. *Am J Psychiatry* 2003;160:1-60.
- American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: Author.
- American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: Author.
- American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
- American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th-TR ed.). Washington, DC: Author.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Arlington, Va. 2012 [29-Sep-2012] <http://www.dsm5.org/Pages/Default.aspx>.
- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. *Am J Psychiatry* 2004;161:111-114.
- American Psychiatric Association. The practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging. A Task Force report. Washington, DC: APA Press 1990.
- Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* 2010;67:146-154.
- Anderson CM, Griffin S, Rossi A, Pagonis I, Holder D, Trieber R. A comparative study of the impact of education vs. process groups for families of patients with affective disorders. *Fam Process* 1986;25:185-205.
- Anderson CM, Hogarty G, Bayer G, Needleman R. Expressed emotion and the social networks of parents of schizophrenic patients. *Br J Psychiatry* 1984;144:247-255.
- Anderson CM. A psychoeducational program for families of patients with schizophrenia. In W. R. McFarlane (Ed.), *Family therapy in schizophrenia*. New York: Guilford Press 1983;99-116.
- Andreasen N. Standardized remission criteria in schizophrenia. *Acta Psychiatr Scand* 2006;113:181.
- Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings and mechanisms. *Arch Gen Psychiatry* 1995;52:341-351.
- Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. *Am J Psychiatry* 2005;162:441-449.
- Andreasen NC, Grove WM. Thought, language, and communication in schizophrenia: diagnosis and prognosis. *Schizophr Bull* 1986;12:348-359.
- Andreasen NC. Standardized remission criteria in schizophrenia. *Acta Psychiatr Scand* 2006;113:181.
- Andreasen NC. The Scale for the Assessment of Negative Symptoms (SAPS). University of Iowa, Iowa City. 1984.
- Andreasen NC. Thought, Language and Communication disorders. I. Clinical assessment, definition of terms and evaluation of their reliability. *Arch Gen Psychiatry* 1979;36:1315-1321.
- Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet* 1987;2:1483-1486.
- Apiquian R, Cordoba R, Louza M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. *Neuropsychiatr Dis Treat* 2010;7:19-26.
- Apiquian R, Fresan A, García-Anaya M, Loyzaga C, Nicolini H. Impacto de la duración de la psicosis no tratada en pacientes con primer episodio psicótico: Estudio de seguimiento a un año. *Gac Med Mex* 2006;142(2):113-120.
- Apiquian R, Fresán A, Ulloa RE, García-Anaya M, Loyzaga C, Nicolini H, Ortega-Soto HA. Comparative study of schizophrenic patients with and without depression. *Salud Mental* 2001;24:25-29.
- Apiquian R, Fresán A, Ulloa RE. Diagnosis and treatment of patients with first psychotic episode. *Salud Mental* 1999;22:79-87.
- Apiquian R, Ulloa RE, Paez F. The Mexican first-episode psychotic study: clinical characteristics and premorbid adjustment. *Schizophr Res* 2002;53:161-163.
- Apiquian R. Escalas de evaluación de Movimientos Anormal. En: Apiquian R, Fresán A, Nicolini H. Evaluación de la Psicopatología. Escalas en español, JGH editores. 2000;89-95.
- Arana GW. An overview of side effects caused by typical antipsychotics. *J Clin Psychiatry* 2000;61(Suppl)8:5-11.
- Arango C, Gómez-Beneyto M, Brenlla J, Gastó C, Sarameacrespo F, Chamorro L et al. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the

- effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. *Eur Neuropsychopharmacol* 2007;17:456-463.
- Arendt M, Rosenberg M, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. *Br J Psychiatry* 2005;187:510-515.
- Aronson JK. Editors' view. Compliance, concordance, adherence. *Br J Clin Pharmacol* 2007;63:383-384.
- Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescent and risk for adult psychosis: longitudinal prospective study. *BMJ* 2002;325:1212-1213.
- Arseneault L, Cannon M, Fischer HL, Polanczyk G, Moffitt TE, Caspi A. Childhood trauma and children's emerging psychotic symptoms: A genetically sensitive longitudinal cohort study. *Am J Psychiatry* 2011;168:65-72.
- Arseneault L, Moffitt TE, Caspi A, Taylor PJ, Silva PA. Mental disorders and violence in a total birth cohort: results from the Dunedin Study. *Arch Gen Psychiatry* 2000;57:979-986.
- Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S et al. Clozapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev* 2010;11:CD006633.
- Astrom-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. *Pharmacoeconomics and Drug Safety* 2008;17:587-592.
- Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. *J Clin Psychiatry* 2011;72:458-463.
- Atkinson JM, Coia DA, Gilnu WH, Harper JM. The impact of education groups for people with schizophrenia on social functioning and quality of life. *Br J Psychiatry* 1966;168:199-204.
- Ayala H, Chism K, Cárdenas G. Una alternativa al tratamiento y rehabilitación de enfermos mentales crónicos. *Salud Mental* 1982;5:1-10.
- Bachrach L. Psychosocial rehabilitation and psychiatry in the treatment of schizophrenia. *Acta Psychiatrica Scand* 2000;102:6-10.
- Bae SW, Brekke J, Bola J. Ethnicity and treatment outcome variation in schizophrenia: a longitudinal study of community - based psychosocial rehabilitation interventions. *J Nerv Ment Dis* 2004;192:623-628.
- Baeza I, Flamarique I, Garrido JM, Horga G, Pons A, Bernardo M et al. Clinical experience using electroconvulsive therapy in adolescents with schizophrenia spectrum disorders. *J Child Adolesc Psychopharmacol* 2010;20:205-209.
- Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. *Journal Clin Psychiatry* 1992;53:439-442.
- Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. *PLoS One* 2011;6.
- Balbo E. Salud mental e inmigración magrebí. *Salud Global* 2004;4:2-7.
- Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R. Is adolescent-onset first-episode psychosis different from adult onset? *J Am Acad Child Adolesc Psychiatry* 2005;44:782-789.
- Ballus C, Llovet JM, Boada JC. La orientación terapéutica familiar en la esquizofrenia: Un modelo psicoeducativo sistémico. Reflexiones tras un año de seguimiento. *Rev Psiquiatría Fac Med Bara* 1991;18:71-78.
- Bankole A, Cohen CI, Vahia I, Diwan Spelekar N, Pelekar N, Reyes P et al. Symptomatic remission in a multi-racial urban population of older adults with schizophrenia. *Am J Geriatr Psychiatry* 2008;16:966-973.
- Bannon MJ, Roth R. Pharmacology of mesocortical dopamine neurons. *Pharmacol Rev* 1983;35:63-68.
- Barch DM, Carter CS, MacDonald AW 3rd, Braver TS, Cohen JD. Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. *J Abnorm Psychol* 2003;112:132-143.
- Barrowclough C, Tarrier N. Families of schizophrenic patients: Cognitive behavioral intervention 1992. London: Chapman & Hall.
- Bauml J, Frobose T, Sibylle K, Rentrop M. Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families. *Schizophr Bull* 2006;32: S1-S9.
- Bell M, Tsang H, Tamasine G, Bryson GJ. Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia. *Schizophr Bull* 2009;35:738-747.
- Bellack A, Mueser KT. Psychosocial Treatment for Schizophrenia. *Schizophr Bull* 1993;19:317-336.
- Bellack AS, Bennett ME, Gearson JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioural treatment for drug abuse in people with severe persistent mental illness. *Arch Gen Psychiatry* 2006;63:426-432.
- Bellack AS, Mueser KT, Gingerch S, Agresta J. Social skills training for schizophrenia. A step by step guide. New York: Guilford Press; 2004.
- Bellack AS, Mueser KT. A comprehensive treatment program for schizophrenia and chronic mental illness. *Community Mental Health J* 1993;22:175-189.
- Benítez CE, Chávez LE, Ontiveros UM. Crianza y esquizofrenia. *Salud Mental* 2005;28:59-72.
- Berman I, Kalinowski A, Berman SM, Lengua J, Green AI. Obsessive and compulsive symptoms in chronic schizophrenia. *Compr Psychiatry* 1995;36:6-10.
- Berman I, Merson A, Viegner B, Losonczy MF, Pappas D, Green AI. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. *J Nerv Ment Dis* 1998;186:150-156.
- Berman I, Sapers B, Chang H, Losonzy M, Schmilder J, Green A. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. *J Clin Psychopharmacol* 1995;15:206-210.
- Bermanzohn P. Prevalence and prognosis of obsessive-compulsive phenomena in schizophrenia: A critical view. *Psychiatric Ann* 1999;29:5508-512.
- Bermanzohn PC, Porto L, Arlow PB. Are some neuroleptic refractory symptoms in schizophrenia really obsessions? *CNS spectrum* 1997;2:51-57.
- Bernardo M, Azanza JR, Rubio TC, Rejas J. Cost-effectiveness analysis of schizophrenia relapse prevention. An economic evaluation of the ZEUS (Ziprasidone-extended-use in schizophrenia) Study in Spain. *Clin Drug Invest* 2006;26:447-457.
- Berrettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. *Biol Psychiatry* 2000;15:48:531-538.
- Berrios GE. Obsessive compulsive disorder: Its Conceptual History in France during the 19th century. *Comprehensive Psychiatry* 1989;30:283-295.
- Berrios GE. The History of Mental Symptoms. First edition. Great Britain Cambridge University Press. 1996.
- Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. *Drugs* 2001;61:111-161.
- Binder RL. Are the mentally ill dangerous? *J Am Acad Psychiatry Law* 1999;27:189-201.
- Birchwood M, Smith J, MacMillan F. Predicting relapse in schizophrenia; the Development and implementation of an early signs monitoring system using patients and family as observers, a preliminary investigation. *Psychol Med* 1989;19:649-656.
- Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. *Br J Psychiatry Suppl* 1998;172:53-59.
- Bishnoi M, Chopra K, Kulkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zipilidone in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:1130-1138.
- Blaschke D, Parwani AS, Huemer M, Rolf S, Boldt LH, Dietz R et al. Torsade de pointes during combined treatment with risperidone and citalopram. *Pharmacopsychiatry* 2007;40:294-295.
- Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. *Nat Genet* 1998;20:70-73.
- Bobes J, Cañas F, Rejas J, Mackell J. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone and haloperidol in Spain. *Prog Neuropsychopharmacol Biol Psychiatry* 2004;28:1287-1297.
- Bobes J, Rejas J, García GM, Rico VF, García PM, Fernández I et al. Weight gain in schizophrenic patients treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. *Schizophr Res* 2003;62:77-88.
- Bond GR, Becker DR, Drake RE. Implementing supported employment as an evidence-based practice. *Psychiatr Serv* 2001;52:313-322.
- Borison RL. Recent advances in the pharmacotherapy of schizophrenia. *Harv Rev Psychiatry* 1997;4:255-271.
- Bottas A, Cooke RG, Richter MA. Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? *J Psychiatry Neurosci* 2005;30:187-193.
- Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. *Am J Psychiatry* 2001;158:2033-2037.
- Bradford DW, Chakos MH, Sheitman BB, Lieberman JA. Atypical antipsychotic drugs in treatment-refractory schizophrenia. *Psychiatric Ann* 1998;28:618-626.
- Brady K, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J. Cocaine abuse among schizophrenic patients. *Am J Psychiatry* 1990;147:1164-1167.
- Braga RJ, Petrides G. Psychiatry Research Department, The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. *J ECT* 2005;21:75-83.
- Bräuning P, Krüger S, Shugar G. Prevalence and clinical significance of catatonic symptoms in mania. *Compr Psychiatry* 1998;39:35-46.
- Brennan PA, Mednick SA, Hodgins S. Major mental disorders and criminal violence in a Danish birth cohort. *Arch Gen Psychiatry* 2000;57:494-500.
- Brenner HD, Pfammatter M. Psychological Therapy in schizophrenia: What is the evidence? *Acta Psychiatr Scand* 2000;102:74-77.
- Briand C, Vasiladis HM, Lesage A, Lalonde P, Stip E, Nicole L. Including integrated psychological treatment as part of standard medical therapy for patients with schizophrenia: Clinical outcomes. *J Nerv Ment Dis* 2005;194:463-470.
- Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M et al. Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia. *Arch Gen Psychiatry* 2004;61:774-780.
- Brown AS, Derkatis EJ. Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies. *Am J Psychiatry* 2010;167:261-280.
- Brown GW. The mental hospital as an institution. *Br J Psychiatry* 1977;130:1-18.
- Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. *Br J Psychiatry* 2000;177:212-217.
- Brunette M, Drake R. Gender Differences in patients with schizophrenia and substance abuse. *Compr Psychiatry* 1997;38:109-116.
- Brunner E, Ortega HA, Apiquian R. Utilidad de la Escala para Acatasia de Barnes en población mexicana. Comunicación personal 1995.
- Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21 - q22. *Science* 2000 288:678-682.

- Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome. *Schizophr Bull* 2002;28:63-74.
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statement. *Schizophr Bull* 2010;36:71-93.
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al. Quality of life after electroconvulsive therapy in persons with treatment resistant schizophrenia. *Indian J Med Res* 2011;133:641-644.
- Buckley P, Thompson PA, Way L, Meitzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine. *Am J Psychiatry* 1994;151:385-389.
- Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When Symptoms Persist: Clozapine Augmentation Strategies. *Schizophr Bull* 2001;27(4):615-628.
- Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. *J Subst Abuse Treat* 1998;15:113-116.
- Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. *J Clin Psychiatry* 2008;69(Suppl)1:4-17.
- Bulbena A, Berrios G, Fernández P. Medición clínica en psiquiatría y psicología. Masson. Barcelona.2000.
- Burgoyne K, Aduri K, Ananth J, Parameswaran S. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. *Curr Pharm Des* 2004;10:2239-2248.
- Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. *BMJ* 2007;335:336.
- Burns T, Creed F, Fahy T, Thompson S, Tyrer P, White I. Intensive versus standard case management for severe psychotic: a randomized trial. *Lancet* 1999;353:2158-2169.
- Burns T, Fioritti A, Holloway F, Malm U, Rossler W. Case management and assertive community treatment in Europe. *Psychiatr Serv* 2001;52:631-636.
- Burns T. Community mental health teams. A guide to current practices. New York: Oxford University Press; 2005. Consultado en <http://www.thecommunityguide.org/library/pubstopic.htm>. Consultado el 5 de junio de 2012.
- Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I Rating scale and standardized examination. *Acta Psychiatr Scand* 1996;93:129-136.
- Butzlaff RL, Hooley JM. Expressed emotion and psychiatric relapse: a meta-analysis. *Arch Gen Psychiatry* 1998;55:547-552.
- Bye R, Linares E. Plantas medicinales del México prehispánico. *Arqueología mexicana* 1999;7:4-11.
- Byne W, Hazlett EA, Buchsbaum MS, Kemether E. The thalamus and schizophrenia: current status of research. *Acta Neuropsychol* 2009;117:347-368.
- Byrne P. Managing the acute psychotic episode. *BMJ* 2007;334:686-692.
- Caldwell CB, Gottesman II. Schizophrenia-a high risk factor for suicide: clues to risk reduction. *Suicide Life Threatening Behaviour* 1992;22:479-493.
- Cannon M, Jones P, Murria R. Obstetric complications and schizophrenia: Historical and meta-analytic review. *Am J Psychiatry* 2002;159:1080-1092.
- Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. *Arch Gen Psychiatry* 2008;65:28-37.
- Cannon TD, Kaprio J, Longqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort: A population based modeling study. *Arch Gen Psychiatry* 1998;55:67-74.
- Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. *Schizophr Res* 2001;48:69-82.
- Caqueo UA, Gutiérrez MJ, Miranda CC. Quality of life in caregivers of patients with schizophrenia: a literature review. *Health Qual Life Outcomes* 2009;7:84.
- Carlsson A, Lindquist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. *Acta Pharmacol Toxicol* 1963;20:140-144.
- Caroff S, Hurlford I, Lybrand J, Campbell C. Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. *Neurol Clin* 2011;29:127.
- Caroff SN, Walker P, Campbell C. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. *J Clin Psychiatry* 2007;68:410-415.
- Caroff SN. Review: extrapyramidal side effects vary between different second-generation antipsychotic drugs. *Evid Based Ment Health* 2012;15:47.
- Carone BJ, Harrow M, Westermeyer JF. Posthospital course and outcome in schizophrenia. *Arch Gen Psychiatry* 1991;48:247-253.
- Carpenter WT, Heinrichs DW, Wagman DW. Deficit and non-deficit forms of schizophrenia: the concept. *Am J Psychiatry* 1988;145:578-583.
- Carr V, Lewin T, Neil A, Halpin S, Colmes S. Premorbid, psychosocial and clinical predictors of the cost of schizophrenia and other psychoses. *Br J Psychiatry* 2004;184:517-525.
- Carr VI, Lewin T, Neil AL, Halpin SA, Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. *Br J Psychiatry* 2004;184:517-525.
- Carter DM, Nackinnon A, Howard S, Zeegers T, Copolov DL. The development and reliability of the Mental Health Research Institute Unusual Perceptions Schedule (MUPS): an instrument to record auditory hallucinatory experience. *Schizophr Res* 1995;16:157-165.
- Carter NJ. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. *Drugs* 2012;72:1137-1160.
- Casas M, Gutiérrez M, Gibert J, Bobes J, Roncero C, Octavio I. Risperidona en el tratamiento de pacientes psicóticos con abuso y dependencia de opiáceos. *Actas Esp Psiquiatr* 2001;29:380-385.
- Casas M. Utilidad de la risperidona en patología dual. III Congreso Nacional de la Sociedad Española de Psiquiatría. Platja d'Aro, España, 20-24 de Octubre, 1998.
- Case M, Stauffer S, Ascher-Svanum H, Conley R, Kapur S, Kane J et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. *Psychol Med* 2011;41:1291-1300.
- Cassano G, Pini S, Rucci P, Dell'Oso L. Occurrence and clinical correlates of psychiatric co-morbidity in patients with psychotic disorders. *J Clin Psychiatry* 1998;59:60-68.
- Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. *Schizophr Bull* 2010;36:1001-1008.
- Castle DJ, Murray RM. The epidemiology of late onset schizophrenia. *Schizophr Bull* 1993;19:691-700.
- Cavallaro R, Cavedini P, Mistretta P, Bassi T, Angelone SM, Ubbiali A. Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study. *Biol Psychiatry* 2003;54:437-443.
- Chabroux S, Haffen E, Penfornis A. Diabetes and second-generation (atypical) antipsychotics. *Annales d'endocrinologie* 2009;70:202-210.
- Chakos MH, Mayerhoff DJ, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. *Psychopharmacol Bull* 1992;28:81-86.
- Chan J, Sweeting M. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. *J Psychopharmacol* 2007;21:657-664.
- Chanpattana W, Chakrabhand ML, Buppanharun W, Sackeim HA. Effects of stimulus intensity on the efficacy of bilateral ECT in schizophrenia: a preliminary study. *Biol Psychiatry* 2000;48:222-228.
- Chanpattana W, Chakrabhand ML. Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome. *Psychiatry Res* 2001;105:107-115.
- Chaves MP, Crippa JA, Morais SL, Zuairi AW. Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder. *J Clin Psychiatry* 2005;66:542-543.
- Chávez-Alvarado C, Pol-Morales F, Villaseñor-Bayardo SJ. Otros conceptos de enfermedad mental. *Investigación en salud* 2005;7:128-134.
- Chen E, Berrios GE. Recognition of hallucinations: a new multidimensional model and methodology. *Psychopathol* 1996;29:54-63.
- Chong SA, Remington G. Clozapine Augmentation: Safety and Efficacy. *Schizophr Bull* 2000;26:421-440.
- Chue P, Chue J. A review of paliperidone palmitate. *Expert Rev Neurother* 2012;12:1383-1397.
- Chue P, Welch R, Lind J. Investigation of the metabolic effects of antipsychotics in patients with schizophrenia. *J Eur Coll Neuropsychopharmacol* 2003;13(suppl 4):S300.
- Chue PS, Heeg B, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. *Pharmacoeconomics* 2005;23(Suppl 1):62-74.
- Chung AKK, Chua SE. Torsade de pointes with low-dose amisulpride: a case report. *J Psychopharmacol* 2010;24:433-435.
- Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM et al. The impact of obesity on health care costs among persons with schizophrenia. *Gen Hosp Psychiatry* 2009;31:1-7.
- CIE-10. The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research, OMS, 1992.
- Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. *Adv Ther* 2009;26:739-48.
- Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM. Neuroleptic drug effects on cognitive function in schizophrenia. *Schizophr Res* 1990;3:211-219.
- Cohen AS, Saperstien AM, Gold JM, Kirkpatrick B, Carpenter WT, Buchanan RW. Neuropsychology of the deficit syndrome: New data and meta-analysis of findings to date. *Schizophr Bull* 2006;33:1201-1212.
- Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. *J Clin Psychiatry* 2012;73:1307-1312.
- Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. *Acta Psychiatr Scand* 2002;106:286-290.
- Colli AM. Psicoterapia intercultural con los espiritistas y practicantes de religiones de origen africano: los aportes de la psicología transpersonal, la etnopsiquiatría y la antropología cultural para su práctica. Ponencia al I Evento Franco-Cubano de Psiquiatría y Psicología, Seminario de Transculturación, Academia de Ciencias de Cuba. Consultado el 13-12-05 en: http://www.click.vi.it/sistemieculture/Mario_Colli_Alonso.html
- Commander M, Sashidharan S, Rana T, Ratnayake T. North Birmingham assertive outreach evaluation. Patient characteristics and clinical outcomes. *Soc Psychiatry Psychiatr Epidemiol* 2005;40:988-993.
- Committee on Safety of Medicines Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). *Curr Prob Pharmacovigilance* 1993;19:9.
- Conley R, Gale E, Hirsch K. Olanzapine response in therapy-refractory schizophrenia with substance abuse. *Schizophr Res* 1998;33:95-101.
- Contopoulos-Loannidis D, Phil S, Trikalinos T, Churchill R, Wahlbeck K, Loannidis J. Comparison of large versus smaller randomized trials for mental health-related interventions. *Am J Psychiatry* 2005;162:578-584.

- Convit A, Isay D, Otis D, Volavka J. Characteristics of repeatedly assaultive psychiatric inpatients. *Hosp Community Psychiatry* 1990;41:1112-1115.
- Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. *Schizophr Bull* 2007;33:688-702.
- Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. *J Clin Psychiatry* 2007;68:546-557.
- Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. *J Clin Psychiatry* 2011;72:655-670.
- Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. *Am J Psychiatry* 2004;161:414-425.
- Correll CU, Manu P, Olshansky V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA* 2009;302:1765-1773.
- Correll CU, Penzner JB, Parikh UH. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. *Child Adolesc Psychiatry Clin N Am* 2006;15:177-206.
- Craib-Meléndez D. Síntomas Obsesivo-Compulsivos en Pacientes con Diagnóstico de Esquizofrenia: prevalencia, características clínicas y sociodemográficas. México D.F.: Universidad Nacional Autónoma de México; 2006.
- Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. *Hist Psychiatry* 2007;18:39-60.
- Crow TJ. Schizophrenia as failure of hemispheric dominance for language. *Trends Neurosci* 1997;20:339-343.
- Crump C, Winkleby M, Sundquist K, MD, Sundquist J. Comorbidities and Mortality in Persons with Schizophrenia: A Swedish National Cohort Study. *Am J Psychiatry* 2013;10.1176/appi.ajp.2012.12050599.
- Cummings JL. Frontal-subcortical circuits and human behavior. *Arch Neurol* 1993;50:873-880.
- Cunningham Owens DG. A Guide to the Extrapiramidal Side-Effects of Antipsychotic Drugs. Cambridge University Press 1999;18-238.
- Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. *J Psychiatr Pract* 2006;12:223-228.
- Dalman C, Allebeck P, Gunnell D, Harrison G, Kristensson K, Lewis G et al. Infections in the CNS During Childhood and the Risk of Subsequent Psychotic Illness: A Cohort Study of More Than One Million Swedish Subjects. *Am J Psychiatry* 2008;165:59-65.
- Das S, Saravanan B, Karunakaran KP, Manoranjitham S, Ezhilarasu P, Jacob KS. Effect of a structured educational intervention on explanatory models of relatives of patients with schizophrenia. Randomised controlled trial. *Br J Psychiatry* 2006;188:286-287.
- Dassori AM, Miller AL, Saldaña D. Schizophrenia among Hispanics: epidemiology, phenomenology, course and outcome. *Schizophr Bull* 1995;21:303-312.
- Daughton J, Padala P, Gabel T. Careful Monitoring for Agranulocytosis During Carbamazepine Treatment. *Prim Care Companion J Clin Psychiatry* 2006;8:310-311.
- David AS. Insight and psychosis. *Br J Psychiatry* 1990;156:798-808.
- Davies LM, Drummond MF. Economics and schizophrenia: the real cost. *Br J Psychiatry* 1994;165:18-21.
- Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry* 2003;60:553-564.
- Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacol* 2004;24:192-208.
- Davis JM, Chen N. Old versus new: weighing the evidence between the first- and second-generation antipsychotics. *Eur Psychiatry* 2005;20:7-14.
- Davis JM, Leucht S, Glick ID. CATIE findings revisited. *Psychiatr Serv* 2009;60:125-126.
- Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. *Schizophr Bull* 1980;6:70-87.
- Davis JM. The choice of drugs for schizophrenia. *N Engl J Med* 2006;354:518-520.
- Davis JM. The use of depot medications in the treatment of schizophrenia. *Am J Psychiatry* 2010;167:125-126.
- Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. *Am J Psychiatry* 1991;148:1474-1486.
- Dawkins K, Lieberman JA, Lebowitz BD, Hsiao JK. Antipsychotics: Past and Future. *Schizophrenia Bull* 1999;25:395-405.
- Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. *Expert Opin Pharmacother* 2008;9:1451-1462.
- De Gregorio C, Morabito G, Cerrito M, Dattilo G, Oretto G. Citalopram-induced long QT syndrome and torsade de pointes: Role for committant therapies and illnesses. *Int J Cardiol* 2011;148:226-228.
- De Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booi J, van Amelsvoort T. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. *Can J Psychiatry* 2004;49:290-296.
- De Hert M, Wampers M, van WR, Peuskens J. Anticholinergic use in hospitalised schizophrenic patients in hospitalised schizophrenic patients in Belgium. *Psychiatry Res* 2007;152:165-172.
- De la Fuente JR. Los fundamentos biológicos de la psiquiatría en perspectiva. *Rev Residente de Psiquiatría* 1992;3:7.
- De la Higuera RJ. Psicoeducación familiar en la esquizofrenia: de los datos empíricos a la realidad clínica. *Apunt Psicol*;2005:275-292.
- De Leo D, Spahonis K. Do psychosocial and pharmacological interventions reduce suicide in schizophrenia and schizophrenia spectrum disorders? *Arch Suicide Res* 2003;7:353-374.
- De Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. *Expert Opin Drug Metab Toxicol*. 2012;8:311-334.
- Delawalla Z, Barch DM, Fisher Eastep JL, Thomason ES, Hanewinkel MJ, Thompson PA et al. Factors mediating cognitive deficits and psychopathology among siblings of individuals with schizophrenia. *Schizophr Bull* 2006;32:525-537.
- Delisi LE. First-episode schizophrenia and depression. *Am J Psychiatry* 1995;152:476-477.
- Demler TL, Trigoboff E. Are clozapine blood dyscrasias associated with concomitant medications? *Innov Clin Neurosci* 2011;8:35-41.
- Deniker P. Discovery of the clinical use of neuroleptics. In: Parnham MJ, Bruinvels J, editors. *Discoveries in pharmacology, Vol. I. Psycho- and neuropharmacology*. Amsterdam: Elsevier 1983:163-180.
- Department of Health. Care services improvement partnership. Reviewing the care program approach 2006. A consultation document. London (United Kingdom) 2006, consultado en <http://www.bipsolutions.com/docstore/pdf/14895.pdf> el 26 de junio del 2012.
- Derinöz O, Caglar AA. Drug-induced movement disorders in children at paediatric emergency department: 'dystonia'. *Emerg Med J* 2012.
- Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. *BMC Psychiatry* 2010;10:43.
- Deveci A, Esen-Danaci A, Yurtseven F. The effects of psychosocial skills training on symptomatology, insight, quality of life, and suicide probability in schizophrenia. *Turk Psikiyatri Derg* 2008;19:1-8.
- Devereux G. Les facteurs culturels en therapeutique psychanalytique. En *Essais d'Etnopsychiatrie*. Paris: Ed. Gallimard; 1970.
- Díaz M, Ortega S, Rodríguez V. El tratamiento integral del paciente esquizofrénico. *Salud Mental* 2005;06:35-70.
- Díaz MR, Ortega SH, Rascón ML. La Rehabilitación Integral del paciente esquizofrénico en México. El Modelo del Instituto Nacional de Psiquiatría Ramón de la Fuente. Grupo III. *Salud Mental* 2005;28:9-19.
- Díaz R, López JL, Reyes RC. Necesidad de dar atención a los familiares responsables del cuidado de pacientes esquizofrénicos. *Suplemento de la Revista Salud Mental* 1997;2:55-64.
- Díaz R, Rascón ML, Ortega H, Murow E, Valencia M, Ramírez I. Evaluación de un programa de rehabilitación del paciente esquizofrénico. *Rev. Fac Med UNAM* 1998;41:51-59.
- Díaz R, Ramos L. La violencia doméstica en familiares de pacientes con esquizofrenia. *Gaceta Médica de México* 2003;139:371-376.
- Díaz R, Rascon ML, Valencia M, Unikel C, Murow E, Rascon D, Leños C, Ortega H. El programa de rehabilitación integral del paciente esquizofrénico del Instituto Mexicano de Psiquiatría. Seguimiento a dos años. *Salud Mental* 1999;22:104-113.
- Díaz R, Murow E, Ortega H, Valencia M, Rascón ML, Ramírez I. El manejo integral del paciente esquizofrénico. Un modelo del Instituto Mexicano de Psiquiatría. *Salud Mental* 1996;19:1-7.
- Dickey B, Azeni H, Weiss R, Sederer L. Schizophrenia, substance use disorders and medical co-morbidity. *J Ment Health Policy Econ* 2000;3:27-33.
- Dilk MN, Bond GR. Meta-analytic evaluation of skills training research for individuals with severe mental illness. *J Consult Clin Psychol* 1996;64:1337-1346.
- Dixon L, Dickerson F, Bellack A. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements. *Schizophr Bull* 2010;36:48-70.
- Dixon L, Adams C, Lucksted A. Update of family psychoeducation for schizophrenia. *Schizophr Bull* 2000;26:5-20.
- Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. *Br J Clin Pharmacol* 2008;66:396-404.
- Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? *Am J Psychiatry* 2002;159:103-108.
- Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. *Am J Emerg Med* 2000;18:227-229.
- Drake R, Bond G, Essock S. Implementing Evidence Based Practices for People With Schizophrenia. *Schizophr Bull* 2009;35:704-713.
- Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. *J Nerv Ment Dis* 1989;177:408-414.
- Drake RE, Xie H, McHugo GJ, Green AL. The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. *Schizophr Bull* 2000;26:441-449.
- Drake RE. Suicide attempts and completed suicides among schizophrenia patients. In: Tatarelli R, Pompili M, Girardi P (eds). *Suicide in Schizophrenia*. New York: Nova Science Publishers; 77-81.
- Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Economic evaluation using decision analytic modelling. En *Methods for the economic evaluation of health care programmes*. New York: Oxford University Press;2005:278-322.
- DSM-IV-TR. Diagnostic and statistical manual of mental disorders: 4th ed., text revision. ed. Washington, DC: American Psychiatric Association;2000.
- DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Barcelona, Masson, 1998.
- Dulcan MK, Martini DR, Lake M. Child and Adolescent Psychiatry. Third edition. United States of America 2003.
- Dutt A, Grover S, Chakrabarti S, Avasthi A, Kumar S. Phenomenology and treatment of Catatonia: A descriptive study from north India. *Indian J Psychiatry* 2011;53:36-40.

- Edwards J, Maude D, McGorry PD, Harrigan SM, Cocks JT. Prolonged recovery in first-episode psychosis. *Br J Psychiatry Suppl* 1998;172:107-116.
- Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. *Curr Med Res Opin* 2008;24:3341-3355.
- Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA. Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. *Am J Psychiatry* 1997;154:271-273.
- Ekelund J, Hovatta I, Parker A, Paunio T, Varilo T, Martin R et al. Chromosome 1 loci in Finnish schizophrenia families. *Hum Mol Genet* 2001;10:1611-1617.
- Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. *Int Clin Psychopharmacol* 2008;23:325-331.
- Endler NS. The Origins of Electroconvulsive Therapy (ECT). *Convsuls Ther* 1988;4:5-23.
- Englisch S, Esser A, Zink M. Bupropion for depression in schizophrenia: a case report. *Pharmacopsychiatry* 2010;43:38-39.
- Enright JB, Jaekle WR. Psychiatric symptoms and diagnosis in two sub-cultures. *International J Soc Psychiatry* 1963;9:12-17.
- Escobar A, Weidenheim K. Esquizofrenia. Circuitos nerviosos anormales. *Rev Mex Neuroci* 2004;5:50-55.
- Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. *Arq Neuropsiquiatr* 2004;62:784-788.
- Fabisch K, Fabisch H, Langs G, Huber HP, Zapotoczky HG. Incidence of obsessive-compulsive phenomena in the course of acute schizophrenia and schizoaffective disorder. *Eur Psychiatry* 2001;16:336-341.
- Falloon I, Montero I, Sungur M, Mastroeni A. Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. *World Psychiatry* 2004;3:104-109.
- Falloon IR, Boyd JL, McGill CW, Williamson M, Razani J, Moss HB et al. Family management in the prevention of morbidity of schizophrenia: Clinical outcome of a two-year longitudinal study. *Arch Gen Psychiatry* 1985;42:887-896.
- Falloon IR, Boyd JL, McGill C. Family care of schizophrenia. Nueva York: Guilford Press; 1984.
- Falloon IR, Laporta M, Fadden G, Graham-Hole V. Managing stress in families: Cognitive and behavioural strategies for enhancing coping skills. London: Routledge; 1993.
- Falloon IR, Liberman RP. Behavioral family interventions in the management of chronic schizophrenia. In: McFarlane WR (ed). Family therapy in schizophrenia. New York: Guilford Press; 1983;117-137.
- Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies. *J Psychiatr Res*. 2013 Aug 14. Doi:pii:S0022-3956(13)00223-9. 10.1016/j.jpsychires.2013.07.011. [Epubahead of print].
- Farah A. Atypicality of Atypical Antipsychotics Prim Care Companion. *J Clin Psychiatry* 2005;7:268-274.
- Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. *Arch Gen Psychiatry* 1988;45:71-76.
- Farde L, Stone-Elender S, Halldin C, Nordström AL, Hall H, Sedvall G. D2 dopamine receptors in neuroleptic-naïve schizophrenic patients: a positron emission tomography study with [11C] raclopride. *Arch Gen Psychiatry* 1990;47:213-219.
- Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. *Arch Gen Psychiatry* 1992;49:538-544.
- FDA. Information for Healthcare Professionals: Haloperidol. FDA ALERT 9/2007. <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm085203.htm>.
- Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. *Suicide Life Threatment Behaviour* 2000;30:34-49.
- Fenton WS, McGlashan TH. Prognostic scale for chronic schizophrenia. *Schizophr Bull* 1987;13:277-286.
- Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. *Am J Psychiatry* 1986;143:437-441.
- Findling RL, Kline K, McKenna K. Efficacy and safety of quetiapine in adolescents with schizophrenia: a 6-week, double-blind, randomized, placebo-controlled trial. Presented at: 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL: October 28 to November 2, 2008.
- Findling RL, Robb A, Niyilas M. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. *Am J Psychiatry* 2008;165:1432-1441.
- Fink M, Sackeim HA. Convulsive Therapy in Schizophrenia? *Schizophr Bull* 1996;22:27-39.
- Fink M. Catatonia: syndrome or schizophrenia subtype? Recognition and treatment. *J Neural Transm* 2001;108:637-644.
- Fink M. Indications for the use of ECT. *Psychopharmacol Bull* 1994;30:269-280.
- Fink M. Meduna and the Origins of Convulsive Therapy. *Am J Psychiatry* 1984;141:1034-1041.
- Fitton A, Heel R. Clozapine: A review of its pharmacological properties and therapeutic use in schizophrenia. *Drugs* 1990;40:722-747.
- Fleischhacker W. Clozapine: A comparison with other novel antipsychotics. *J Clin Psychiatry* 1999;60:30-34.
- Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. *Encephale* 2000;26:12-14.
- Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman J, Pollack S et al. Clozapine dose in the US and Europe: Implications for therapeutic and adverse effects. *J Clin Psychiatry* 1994;55:78-81.
- Fleischhacker WW, Keet IP, Kahn RS. EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. *Schizophr Res* 2005;78:147-156.
- Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. *J Clin Psychiatry* 2003;16:10-13.
- Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. *J Clin psychopharmacol* 1990;10:12.
- Fonseca PE, Campillo AA, Muñoz J, Lemos GS, García CE. Adaptación española del Thinking and Perceptual Style Questionnaire. Libro de Actas del X Congreso de Metodología de las Ciencias Sociales y del Comportamiento. Barcelona 2007.
- Fonseca PE, Lemos GS, Paino M, Sierra BS, Villazón GU, García PM et al. Dimensionality of hallucinatory predisposition: Confirmatory factor analysis of the Launay-Slade Hallucination Scale-revised in college students. *Anales de Psicología* 2010;26:41-48.
- Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. *Drugs* 2010;70:2289-2313.
- Freedman R, Carpenter WT Jr, Davis JM, Goldman HH, Tamminga CA, Thomas M. The costs of drugs for schizophrenia. *Am J Psychiatry* 2006;163:2029-2031.
- Freedman R. The choice of antipsychotic drugs for schizophrenia. *N Engl J Med* 2005;353:1286-1288.
- Fresán A, Apiquian R, Loyzaga C, García-Anaya M, Ulloa RE, Nicolini H. Functional recovery in first-episode psychosis. *Psiquiatría y Salud Integral* 2002;2:40-44.
- Freudenreich O. The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis. *Harv Rev Psychiatry* 2007;15:189-211.
- Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry*. 2012;69(3):220-229. Epub 2012/03/07.
- Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M et al. First vs. multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. *Schizophr Res* 2002;53:145-159.
- Gajwani P, Pozuelo L, Tesar GE. QT interval prolongation associated with quetiapine (Seroquel) overdose. *Psychosomatics* 2000;41:63-65.
- García M. Capítulo 9. Rehabilitación e inserción laboral de personas con esquizofrenia. En: Valencia M (Compilador). Alternativas terapéuticas para la esquizofrenia. Editorial Herder (En Prensa); 2012.
- García P, Bascarán F, Sáiz M, Bousoño GM, Bobes GJ. Instrumentos de evaluación para los trastornos esquizofrénicos. En: Banco de instrumentos básicos para la práctica de la psiquiatría clínica, Tomo 1, España, CYESAN, 2011:57-87.
- Gardner D, Murphy A, O'Donnell H, Centorrino F, Baldessarini R. International Consensus Study of Antipsychotic Dosing. *Am J Psychiatry* 2010;167:686-693.
- Garety PA, Hemsley DR. Characteristics of delusional experience. *Eur Arch Psychiatry Neurol Sci* 1987;236:294-298.
- Gasquet I, Flandre P, Heurtebize N, Deal C, Perrin E, Chartier F et al. Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL. *L'Encephale* 2009;35:25-31.
- Gearing RE, Mian I, Sholonsky A, Barber J, Nicholas D, Lewis R et al. Developing a risk-model of time to first-relapse for children and adolescents with a psychotic disorder. *J N Mental Dis* 2009;197:6-14.
- Gearon JS, Bellak AS. Sex differences in illness presentation, course and level of functioning in substance-abusing schizophrenia patients. *Schizophr Res* 2000;43:65-70.
- Geddes JR, Kendell RE. Schizophrenic subjects with no history of admission to hospital. *Psychol Med* 1995;25:859-868.
- Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study. *Ann Gen Psychiatry* 2008;7:16.
- Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. *Arch Gen Psychiatry* 1995;52:173-187.
- Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C et al. Clozapine vs. chlorpromazine in treatment-naïve, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. *Br J Psychiatry* 2011;199:281-288.
- Girón M, Gómez-Beneyto M. Relationship between family attitudes and social function in schizophrenia: a nine-month follow-up prospective study in Spain. *J Nerv Ment Dis* 2004;192:414-420.
- Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. *Am J Psychiatry* 2001;158:1774-1782.
- Glazer WM, Moore DC, Schooler NR, Brenner LM, Morgenstern H. Tardive dyskinesia. A discontinuation study. *Arch Gen Psychiatry* 1984;41:623-627.
- Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. *Br J Psychiatry* 1990;157:585-592.
- Gleeson J, Larsen TK, McGorry P. Psychological treatment in pre- and early psychosis. *J Am Acad Psychoanal Dyn Psychiatry* 2003;31:229-245.

- Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. *Schizophr Res* 2010;119:79-88.
- Glick ID, Siris SG, Davis JM. Treating schizophrenia with comorbid depressive or demoralization symptoms. *Journal Clin Psychiatry* 2008;69:501.
- Glynn S, Marder S, Liberman P, Blair K, Wirshing W, Wirshing C et al. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. *Am J Psychiatry* 2002;159:829-837.
- Glynn SM, Cohen AN, Niv N. New challenges in family interventions for schizophrenia. *Expert Rev Neurother* 2007;7:33-43.
- Glynn SM, Marder SR, Liberman RP, Blair K, Wirshing DA, Mintz J. Supplementing clinic based skills training for schizophrenia with manualized community support: effects on social adjustment. *Am J Psychiatry* 2002;159:829-837.
- Godoy JF, Muela JA, Godoy D. Capítulo 2. La prevención de recaídas en la esquizofrenia. En: Valencia M (Compilador). *Alternativas terapéuticas para la esquizofrenia*. Editorial Herder (En Prensa); 2012.
- Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. *Schizophr Bull* 1985;11:453-456.
- Goldman-Rakic PS. Working memory dysfunction in schizophrenia. *J Neuropsychiatry Clin Neurosci* 1994;6:348-357.
- Goldstein M. Family Intervention Programs. En: Bellack A. *Schizophrenia, Treatment, Management and rehabilitation*. Orlando, FL: Grunes & Stratton, Inc. Cap. 10; 1984;281-305.
- Goldstein MJ. Psychoeducation and relapse prevention. *Int Clin Psychopharmacol* 1995;9:59-70.
- González E, Castro N, Ramírez B, Custodio V, Rojas T, Castro R et al. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients. *Arzneimittelforschung* 2011;61:335-339.
- Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. *Expert Opin Pharmacother* 2002;3:479-498.
- Goodwin RD, Amador XF, Malaspina D, Yale SA, Goetz RR, Gorman JM. Anxiety and substance use comorbidity among inpatients with schizophrenia. *Schizophr Res* 2003;61:89-95.
- Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. *Int Clin Psychopharmacol* 2010;25:247-256.
- Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. *J Psychopharmacol* 2011;25:685-697.
- Goswami U, Kumar U, Singh B. Efficacy of Electroconvulsive Therapy in Treatment Resistant Schizophrenia: A double-blind study. *Indian J Psychiatry* 2003;45:26-29.
- Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G. Olanzapine, risperidone and haloperidol in the treatment of adolescents patients with schizophrenia. *J Neural Transm* 2003;110:545-560.
- Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. *Am J Psychiatry* 2003;160:636-645.
- Grant PM, Hud GA, Perivoliotis D, Stolar NM, Beck A. Randomized Trial to Evaluate the Efficacy of Cognitive Therapy for Low-Functioning Patients With Schizophrenia. *Arch Gen Psychiatry* 2012;69:121-127.
- Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. *Drugs*. 1994;48:253-273.
- Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. *Schizophr Res* 2004;72:41-51.
- Green W, Padron-Gayol M, Hardesty A, Bassiri M. Schizophrenia with childhood onset: a phenomenological study of 38 cases. *J Am Acad Child Adolesc Psychiatry* 1992;31:968-976.
- Greenblatt SH. The development of Hughlings Jackson's approach to diseases of the nervous system 1863-1866: unilateral seizures, hemiplegia and aphasia. *Bull Hist Med* 1977;51:412-430.
- Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modeling studies. *Health Technol Assessm* 2005;9(9):1-156.
- Groeger U. Off-label use of antipsychotics: rethinking "off-label". *Psychiatr Danub* 2007;19:350-353.
- Gross-Isseroff R, Hermesh H, Zohar J, Weizman A. Neuroimaging communality between schizophrenia and obsessive compulsive disorder: a putative basis for schizo-obsessive disorder? *W J Biol Psychiatry* 2003;4:129-134.
- Gründer G, Hippus H, Carlsson A. The 'atypical' of antipsychotics: a concept re-examined and re-defined. *Nat Rev Drug Discov* 2009;8:197-202.
- Guan Y, Camm J. Drug induced QT prolongation and torsades de pointes. *Heart* 2003;89:1363-1372.
- Guía de Práctica clínica sobre la esquizofrenia y el trastorno psicótico incipiente <http://www.guiasalud.es/egpc/esquizofrenia/completa/apartado06/tipos4.html>. Consultado el 2 de julio 2012.
- Guitton B, Perez LL, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. *Mov Disord* 2011;26:2226-2231.
- Gumley A. Park Relapse Prevention in Early Psychosis in Promoting Recovery in Early Psychosis: A practice Manual. Wiley-Blackwell, Chichester; 2009.
- Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. *Drugs* 2002;62:1217-1251.
- Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohmann RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. *Am Heart J* 2007;153:891-899.
- Gupta S, Hendricks S, Kenkel AM, Bhatia SC, Haffke EA. Relapse in schizophrenia: is there a relationship to substance abuse? *Schizophr Res* 1996;20:153-156.
- Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ et al. The Consortium on the Genetics of Schizophrenia: Neurocognitive Endophenotypes. *Schizophr Bull* 2007;33:49-68.
- Gutiérrez L, Valencia CM, Leños GR, Soledad V. Percepción de los familiares del intento y la ideación suicida en sus parientes con esquizofrenia. *Rev. Salud Mental* 2004;27(5).
- Gutierrez RP, Chisholm D, Haro JM, Salvador-Carulla L, Ayuso-Mateos JL. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. *Acta Psychiatr Scand Suppl* 2006;432:29-38.
- Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. *J Child Adolesc Psychopharmacol* 2009;19:611-621.
- Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. *Drugs* 2002;62:1649-1671.
- Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections vs. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. *Br J Psychiatry* 2009;52(Suppl):S20-S28.
- Haddock G, Lewis S. New Psychological Treatments for Schizophrenia. *Adv Psychiatric Treat* 1996;2:110-116.
- Hadi E, Greenberg Y, Sirota P. Obsessive-compulsive symptoms in schizophrenia: prevalence, clinical features and treatment. A literature review. *W J Biol Psychiatry* 2012;13:2-13.
- Hafner H, Heiden W. Epidemiology of schizophrenia. *Can J Psychiatry* 1997;42:139-151.
- Häfner H, Maurer K, Löfller W, Fätkenheuer B, an der Heiden W, Riecher-Rössler A et al. The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. *Br J Psychiatry* 1994;23(Suppl):29-38.
- Häfner H, Maurer K. Detección temprana de la esquizofrenia: datos actuales y perspectivas futuras. *World Psychiatry (ed Esp)* 2006;4:130-138.
- Hafner H, Nowotny B. Epidemiology of early onset schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 1995;245:80-92.
- Hall J, Harris J, Sprengelmeyer R, Sprengelmeyer A, Young A, Santos I et al. Social cognition and FACE processing in schizophrenia. *Br J Psychiatry* 2004;185:169-170.
- Hall W, Degenhardt L. Cannabis and psychosis. *Aust NZ J Psychiatry* 2000;34:26-34.
- Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. *Schizophr Bull* 2006;32:166-178.
- Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. *J Clin Psychopharmacol* 2004;24:62-69.
- Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? *Psychol Med* 2003;33:97-110.
- Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. *Br J Psychiatry* 2001;178:506-517.
- Harvard Medical School. Harvard Mental Health Letter. The psychosocial treatment of Harvey PD, Geyer MA, Robbins TW, Krystal JH. Cognition in schizophrenia: from basic science to clinical treatment. *Psychopharmacol* 2003;169:213-214.
- Harvey PD. Introduction to special issue 4th biennial mt. Sinai conference on cognition in schizophrenia. *Schizophr Res* 2000;43:1-2.
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2013 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *W J Biol Psychiatry* 2013;14:2-44.
- Haug HJ, Wirz JA, Rossler W. Actigraphy to measure day structure as a therapeutic variable in the treatment of schizophrenic patients. *Acta Psychiatr Scand* 2000;102:91-95.
- Haukka JK, Suvisaari J, Lönnqvist J. Family structure and risk factors for schizophrenia: case-sibling study. *BMC Psychiatry* 2004;4:41.
- Hayes RL, McGrath JJ. Cognitive rehabilitation for people with schizophrenia and related conditions. *Cochrane Database Syst Rev* 2000;CD000968.
- Haynes RB, Montague P, Oliver T, McKibbin KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. *Cochrane Database Syst Rev* 2000;(2):CD000011.
- Hegarty JD, Baldessarini RJ, Tohen M, Waterman C, Oepen G. One hundred years of schizophrenia: a metaanalysis of the outcome literature. *Am J Psychiatry* 1994;151:1409-1416.
- Heinrichs RW. The primacy of cognition in schizophrenia. *Am Psychol* 2005;60:229-242.
- Heinssen R, Liberman RP, Kopelowicz A. Psychosocial Skills Training for Schizophrenia: Lessons from the Laboratory. *Schizophr Bull* 2000;26:26-46.
- Heinz A, Knabe MB, Weinberger DR. Dopamine D2 receptor imaging and neuroleptic drug response. *J Clin Psychiatry* 1998;57:84-88.
- Heinze G, Cortés JF. Treatment preference and attitude toward pharmacotherapy and psychotherapy in Latin America. *ULAD task force. Salud Mental* 2005;28:10-17.

- Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *Am J Psychiatry* 2006;163:185-194.
- Herrera MA, García AJ, Gamiochipi CJ, de la Llera VM. Rehabilitación temprana en pacientes hospitalizados en unidades psiquiátricas. *Rev Psiquis México* 1998;7:128-141.
- Herrera-Estrella MA, Viveros-Erosa MA, Castaneda de Alba L, Castillo-Ruiz J, Pérez-Hernández M, López-Rentería A et al. La eficacia del cambio de terapia a risperidona en microesferas de acción prolongada. *Psiquis* 2005;14:51-58.
- Herz M. Prodromal symptoms and prevention of relapse in schizophrenia. *J Clin Psychiatry* 1985;46:22-25.
- Herz MI, Lambert J, Mintz J, Scott R, O'Dell SP, McCartan L, Nix G. A program for relapse prevention in schizophrenia: A controlled study. *Arch Gen Psychiatry* 2000;57:277-283.
- Herz MI. Early interventions in schizophrenia. En: Herz MI, Keith SJ, Docherty JP (eds). *Psychosocial treatment of schizophrenia Vol 4*. Amsterdam: Elsevier Science Publishers; 1990;25-44.
- Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehtikainen P, Ruotsalainen U et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naïve schizophrenic patients studied with positron emission tomography. *Arch Gen Psychiatry* 1994;51:116-123.
- Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Kamali M et al. Nonadherence to medication four years after a first episode of psychosis and associated risk factors. *Psychiatr Serv* 2010;61:189-192.
- Hill M, Freudenreich O. Clozapine: key discussion points for prescribers. *Clin Schizophr Relat Psychoses*. 2013;6:177-185.
- Hoch EM. Comments of special issue on schizophrenia. *Transcult Res Ment Health Probl* 1961;11:6571.
- Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions. Why uncertainty about the outcome, estimate and willingness to pay matters. *Pharmacoeconomics*. 2007;25:807-816.
- Hogan TP, Awad AG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. *Psychol Med* 1983;13:177-183.
- Hogarty G, Kornblith S, Greenwald D, Dibarry A, Cooley S, Ulrich R et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family. I: Description of a study and effects on relapse rates. *Am J Psychiatry* 1997;154:1504-1513.
- Hogarty G, Ulrich R. The Limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. *J Psychiatr Res* 1998;32:243-250.
- Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer A et al. A prospective, multicentre study of patients refusal of antipsychotic medication. *Arch Gen Psychiatry* 1990;47:949-956.
- Hollweg MG. Técnicas del manejo psiquiátrico en una región policultural (Bolivia). *Rev Neuro-Psiqui* 2001;64:165-171.
- Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: A meta-analysis of voxel-based morphometry studies. *Am J Psychiatry* 2005;162:2233-2245.
- Hooley JM. The nature and origins of expressed emotion. En: Hahlweg K, Goldstein MJ (eds). *Understanding major mental disorder: the contribution of family interaction research*. New York: Family Process; 1987:176-194.
- Hossein F, Folsom TD. The Neurodevelopmental Hypothesis of Schizophrenia, Revisited. *Schizophr Bull* 2009;35:528-548.
- Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. *Schizophr Res* 2010;116:107-117.
- Howard R, Rabins PV, Seeman MV, Jeste DV. The International Late-Onset Schizophrenia Group. Late-onset schizophrenia and very-late-onset schizophrenia like psychosis: an international Consensus. *Am J Psychiatry* 2000;157:172-178.
- Howland RH. Drug therapies for tardive dyskinesia: part 2. *J Psychosoc Nurs Ment Health Serv* 2011;49:17-20.
- Huang CC. Risperdal reduces alcohol use in dual disabled schizophrenia patients. *Eur Neuropsychopharmacol* 1996;6:43.
- Huxley N, Rendall M, Sederer LL. Psychosocial Treatments in Schizophrenia. A Review of the Past 20 years. *J Nerv Ment Dis* 2000;188:187-201.
- Hwang MY, Kim SW, Yum SY, Opler LA. Management of schizophrenia with obsessive-compulsive features. *Psychiatric Clin N Am* 2009;32:835-851.
- Hwang MY, Opler LA. Schizophrenia with obsessive-compulsive features: assessment and Hyman S. *Diagnosing Disorders*. Scientific American 2003;289:76-83.
- Jager AC, Kirch DG, Wyatt, RJ. The negative Symptom Rating Scale. *Psychiatry Res* 1985;16:27-36.
- Información para prescribir Inveda Sustenna.
- Insel TR, Akiskal HS. Obsessive-compulsive disorder with psychotic features a phenomenological analysis. *Am J Psychiatry* 1986;143:1527-1533.
- Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. *Br J Psychiatry* 1998;172:35-37.
- Instituto Mexicano del Seguro Social [citado Mar 2006]. Disponible en: www.imss.gob.mx
- Instituto Mexicano del Seguro Social. Secretaría General. Aviso: Costes unitarios de la atención médica. Diario Oficial de la Federación. Martes 9 de marzo de 2004, Primera Sección pp. 106-107 [citado Mar 2004]. Disponible en: <http://dof.gob.mx/> index.php
- Instituto Nacional de Estadística, Geografía e Informática, México. INEGI, 2000.
- International Statistical Classification of Diseases, 10th Revision (ICD-10), Second Edition, WHO.
- Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE et al. Schizophrenia: The 100 year epidemiology of squizophrenia. *Schizpr Res* 1997;28:111-125.
- Jackson C, Knott C, Skeate A, Birchwood M. The trauma of first episode psychosis: the role of cognitive mediation. *Aust N Z J Psychiatry* 2004;38 (5):327-333.
- Jahrreis W. Obsessions during schizophrenia. *Arch Psychiatric Nevenkr* 1926;77:740-788.
- Jarbin H, Von Knorring AL. Suicide and suicide attempts in adolescent-onset psychotic disorders. *Nordic Journal Psychiatry* 2004;58:115-123
- Jarskog L, Selinger E, Lieberman J, Gilmore J. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. *Am J Psychiatry* 2004;161:108-115.
- Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. *Cochrane Database Syst Rev*. 2012 Apr 18;4:CD000525. Doi:10.1002/14651858.CD000525.
- Jeste DV, Caligiuri MP. Biological research in Geriatrics Psychiatry. *Biol Psychiat* 1991;30:855-856.
- Jiang J, See YM, Subramaniam M, Lee J. Investigation of Cigarette Smoking among Male Schizophrenia Patients. *PLoS One* 2013;8:e71343.
- Jilek W. Cultural factors in psychiatric disorders. Presented at the 26th Congress of the World Federation for Mental Health, July 2001. Consultado el 10-12-05, en: www.mentalhealth.com/mag1/wolfgang.html
- Jimeno N, Jimeno A, Vargas, ML. El síndrome psicótico y el inventario de Frankfurt: Conceptos y resultados. España: Springer-Verlag Ibérica; 1996.
- Johns CA, Thompson JW. Adjunctive Treatments in Schizophrenia: Pharmacotherapies and Electroconvulsive Therapy. *Schizophr Bull* 1995;21:607-619.
- Johnstone E, Ebmeier K, Millar P, Owens D, Lawrie S. Predicting schizophrenia: findings from the Edinburgh high-risk study. *Br J Psychiatry* 2005;186:18-25.
- Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al. Randomized controlled trial of the effect on Quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry* 2006;63:1079-1087.
- Jorgensen P. Early signs of psychotic relapse in schizophrenia. *Br J Psychiatry* 1998;172:327-330.
- Jungbauer J, Wittmund B, Dietrich S, Angermeyer MC. The Disregarded Caregivers: Subjective Burden in Spouses of Schizophrenia Patients. *Schizophr Bull* 2004;30:665-675.
- Kahn RS, Davis KL. New development in dopamine and schizophrenia. En: Bloom FF, Kupfer DJ (eds). *Psychopharmacology: The Fourth Generation of Progress*. Cuarta edición. Nueva York: Raven Press; 1995.
- Kallergis EM, Goudis ChA, Simantirakis EM, Kochiadakis GE, Panos EV. Mechanisms, Risk Factors, and Management of Acquired Long QT Syndrome: A Comprehensive Review. *The Scientific World Journal* 2012;1:1-8.
- Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A et al. A prospective evaluation of adherence to medication in first episode schizophrenia. *Eur Psychiatry* 2006;21:29-33.
- Kane J. Treatment Strategies to Prevent Relapse and Encourage Remission. *J Clin Psychiatry* 2007;14:27-30.
- Kane JM, Honigfeld G, Singer J, Meltzer J, Meltzer HY and the Clozaril Collaborative Study Group. Clozapine for the treatment - resistant schizophrenic. *Arch Gen Psychiatry* 1988;45:789-796.
- Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW et al. Clozapine and haloperidol in moderately refractory schizophrenia: A six month double-blind comparison. *Arch Gen Psychiatry* 1999 in press.
- Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2012;73:617-624.
- Kane JM. Problems of compliance in the outpatients treatment of schizophrenia. *J Clin Psychiatry* 1983;44:3-6.
- Kane JM. Utilization of long-acting antipsychotic medication in patient care. *CNS Spectr* 2006;11:1-7.
- Kane, JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ (eds). *Psychopharmacology: the Fourth Generation of Progress*. New York: Raven Press; 1995;1485-1495.
- Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ et al. Electrocardiographic abnormalities in patients treated with clozapine. *J Clin Psychiatry* 2000;61:441-446.
- Kaplan HI, Sadock BJ, Grebb JA. *Sinopsis de Psiquiatría*. 7a. ed. Buenos Aires: Panamericana; 1996;1272.
- Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D-2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. *Life Sci* 1995;57:103-107.
- Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. *Am J Psychiatry* 1996;153:466-476.
- Karamatskos E, Lambert M, Mulert C, Naber D. Drug safety and efficacy evaluation of sertindole for schizophrenia. *Expert Opin Drug Saf* 2012;11:1047-1062.
- Karim S, Overshott R, Burns A. Older people with chronic schizophrenia. *Aging & Mental Health* 2005;9:315-324.
- Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. *Arch Gen Psychiatry* 1988;45:1094-1099.
- Karno M, Golding JM, Sorenson SP, Burnam MA. The epidemiology of obsessive-compulsive disorder in five U.S. communities. *Arch Gen Psychiatry* 1988;45:1094-1099.

- Karvonen K, Sammela HL, Rahikkala H. Sex, timing, and depression among suicide victims with schizophrenia. *Comprehensive Psychiatry* 2007;48:319-322.
- Katschnig H, Freeman H, Sartorius N (eds). *Quality of life in mental disorders*. John Wiley & Sons; 1997.
- Katz MM, Marsella A, Dube KC, Olatawura M, Takahashi R, Nakane Y et al. On the expression of psychosis in different cultures: Schizophrenia in an Indian and in a Nigerian community. *Cult Med Psychiatry* 1988;12:331-355.
- Kavanagh D, McGrath J, Saunders J, Dore G, Clark D. Substance Misuse in patients with schizophrenia. *Drugs* 2002;62:743-755.
- Kawashima T, Nakamura M, Bouix S, Kubicki M, Salisbury DF, Westin CF, McCarley RW, Shenton ME. Uncinate fasciculus abnormalities in recent onset schizophrenia and affective psychosis: a diffusion tensor imaging study. *Schizophr Res* 2009;110:119-126.
- Keck PE, Pope HG, Cohen BM. Risk factors for neuroleptic malignant syndrome. *Arch Gen Psychiatry* 1989;46:914-918.
- Keck PI, Strakowski SM, Celroy SL. The efficacy of atypical antipsychotics in The treatment of depressive symptoms hostility, and suicidality in patients with schizophrenia. *J Clin Psychiatry* 2000;61:4-9.
- Keefe RSE, Bilder RM, Davis SM. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the Catie trial. *Arch Gen Psychiatry* 2007;64:633-647.
- Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. *J Clin Psychiatry* 2003;64:1308-1315.
- Keith SJ, Regier DA, Rae DS. *Schizophrenic disorders*. En: Robins LN, Regier DA. *Psychiatric Disorders in America*. USA: The Free Press; 1991:33-52.
- Kendler KL, Glazer WM, Morgenstern H. Dimensions of delusional experience. *Am J Psychiatry* 1983;140:466-469.
- Kern R, Green M, Mitchell S, Kopelowicz A, Mintz J, Liberman P. Extensions of errorless learning for social problem-solving deficits in schizophrenia. *Am J Psychiatry* 2005;162:513-519.
- Kern S, Liberman P, Kopelowicz A, Mintz J, Green F. Applications of errorless learning for improving work performance in persons with schizophrenia. *Am J Psychiatry* 2002;159:1921-1926.
- Kerwin R. Preventing suicide [letter]. *Br J Psychiatry* 2003;182:366.
- Keshavan M, Duggal H, Veeragandham G, McLaughlin N, Montrose D, Haas L et al. Personality dimensions in first episode psychoses. *Am J Psychiatry* 2005;162:102-109.
- Khashan MS, Abel M, McNamee R, Pedersen MG, Webb RT, Baker PN et al. Higher Risk of Offspring Schizophrenia Following Antenatal Maternal Exposure to Severe Adverse Life Events. *Arch Gen Psychiatry* 2008;65:146-152.
- Killaspy H, Bebbington P, Blizard R, Johnson S, Nolan F, Pilling S et al. The REACT study: randomised evaluation of assertive community treatment in north London. *BMJ* 2006;332:815-820.
- Kim J, Mohamed S, Andreasen N, O'Leary D, Watkins L, Boles Ponto L et al. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. *Am J Psychiatry* 2000;157:542-548.
- Kim SW, Shin IS, Kim JM, Yang SJ, Hwang MY, Yoon JS. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. *J Clin Psychopharmacol* 2008;28:349-352.
- Kimiagar I, Dobronevsky E, Prokhorov T, Miniovitz A, Rabey JM. Rapid improvement of tardive dyskinesia with tetraabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. *J Neurol* 2012;259:660-664.
- Kindermann SS, Karimi A, Symonds L, Brown GG, Jeste DV. Review of functional magnetic resonance imaging in schizophrenia. *Schizophr Res* 1997;27:143-156.
- Kinney DK, Levy DL, Yurgelun-Todd DA, Medoff D, LaJonchere CM, Radford-Paregol M. Season of birth and obstetrical complications in schizophrenics. *J Psychiatr Res* 1994;28:499-509.
- Kirk Morton N, Zubek D. Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia. *J Psychosoc Nurs Ment Health Serv* 2013;51:13-18.
- Kirkpatrick B, Buchanan RW, McKenney PD, Alphas L, Carpenter WT. The schedule for the deficit syndrome an instrument for research in schizophrenia. *Psychiatry Res* 1989;30:119-123.
- Kirkpatrick B, Messias E, Harvey PDE, Fernandez-Egea E, Bowie CR. Is schizophrenia a syndrome of accelerated aging. *Schizophr Bull* 2008;34:1024-1032.
- Kirmayer L. Myth and ritual in psychotherapy. *Transcult Psychiatry* 1999;36:451-460.
- Kitis A, Akdede BB, Alptekin K, Akvardar Y, Arkar H, Erol A et al. Cognitive dysfunctions in patients with obsessive-compulsive disorder compared to the patients with schizophrenia patients: relation to overvalued ideas. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:254-261.
- Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. *Arch Gen Psychiatry* 2001;58:158-164.
- Kluge R, Schwarz S, Hunger H, Schmid F, Kissling W, Leucht S. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head to head comparisons. *Schizophrenia Bull* 2012;38:167-177.
- Knapp M, Mangalore R. The trouble with QALYs... *Epidemiol Psychiatr Soc* 2007;16:289-293.
- Koneru V, Weisman D, Mamani A, Wasserman S, Duarte E, Dunham R, Valencia M. Capítulo 10. Aculturación y la salud mental en los pacientes con esquizofrenia y sus familiares. En Valencia M (Compilador). *Alternativas terapéuticas para la esquizofrenia*. Editorial Herder. México 2012.
- Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone. *J Clin Psychopharmacol* 1997;17:308-313.
- Kopelowicz A, Liberman RP. Integrating Treatment with Rehabilitation for persons With Major Mental Illnesses. *Psychiatr Serv* 2003;54:1491-1498.
- Kopelowicz A, Liberman RP, Zarate R. Recent Advances in Social Skills Training for Schizophrenia. *Schizophr Bull* 2006;32:S12-S23.
- Kopelowicz A, Zarate R, Gonzalez V, Mintz J, Liberman RP. Disease management in latinos with schizophrenia: A family-assisted skills training approach. *Schizophr Bull* 2003;29:211-227.
- Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. *Am J Psychiatry* 1993;150:1643-1648.
- Korf J. Imaging of receptors in clinical neurosciences. *Acta Neurol Belg* 1997;200-205.
- Kraepelin E, Robertson GM. *Dementia praecox and paraphrenia*. Huntington, New York: Krieger; 1971.
- Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. *Int J Neuropsychopharmacol* 2010;13:635-647.
- Kramer M, Simpson G, Maciulis V, Kushner S, Liu Y, Lim P et al. One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia. *CNS Spectr* 2010;15:506-514.
- Kramer, BA. Maintenance electroconvulsive therapy in clinical practice. *Convulsive Ther* 1990;6:279-286.
- Krassoievitch M. Trastornos delirantes en la vejez. Editorial Desclee De Brouwer, S.A. Bilbao, España. 2004;15-40.
- Krausz M, Muller T, Hassen C. Suicide among schizophrenic adolescents in the long-term course of illness. *Psychopathology* 1995;28:95-103.
- Kristensen D, Bauer J, Hageman I, Jorgensen MB. Electroconvulsive therapy for treating schizophrenia: a chart review of patients from two catchment areas. *Eur Arch Psychiatry Clin Neurosci* 2011;261:425-432.
- Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. *Psychiatry Res* 2007;151:151-154.
- Kruger S, Braunig P, Hoffer J, Shugar G, Borner I, Langkrar J. Prevalence of obsessive-compulsive disorder in schizophrenia and significance of motor symptoms. *J Neuropsychiatry Clin Neurosci* 2000;12:16-24.
- Kryzhanovskaya L, Schulz SC, McDougle C. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2009;48:60-70.
- Kubicki M, McCarley R, Westin CF, Park HJ, Maier S, Kikinis R et al. A review of diffusion tensor imaging studies in schizophrenia. *J Psychiatry Res* 2007;41:15-30.
- Kufferle B, Tasucher J, Asenbaum S. IB2M SPECT imaging of striatal D2 receptors in psychotic patients treated with quetiapine in comparison to clozapine and haloperidol. *Psychopharmacol* 1997;133:323-328.
- Kuipers L, Leff J, Lam D. *Family work for schizophrenia: A practical guide*. London: Gaskell; 1992.
- Kuipers L. Family burden in schizophrenia: implications for services. *Soc Psychiatry Psychiatr Epidemiol* 1993;28:207-210.
- Kulhara P, Avasthi A, Sharan P, Gupta N, Raq AS. Late onset schizophrenia versus onset schizophrenia: a comparison of clinical features. *Indian J Psychiatry* 1999;41:333-335.
- Kulhara P, Chakrabarti S, Avasthi A, Sharma A, Sharma S. Psychoeducational intervention for caregivers of Indian patients with schizophrenia: a randomized-controlled trial. *Acta Psychiatr Scand* 2009;119:472-483.
- Kumra S, Jacobsen IK, Lenane M, Zahn TP, Wigs E, Alaghband-Rad J. Multidimensionally impaired disorder. Is it a variant of very early-onset schizophrenia? *J Am Acad Child Adolesc Psychiatry* 1998;37:91-99.
- Kurtz M, Mueser KT. A Meta-Analysis of Controlled Research on Social Skills Training. *J Consult Clin Psychol* 2008;76:491-504.
- Kurz M, Hummer M, Oberbauer H, Fleischhacker WW. Extrapyramidal side effects of clozapine and haloperidol. *Psychopharmacol* 1995;118:52-56.
- Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. *Psychiatr Clin Neurosciences* 2009;63:73-81.
- La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. *N Engl J Med* 2001;345:224-225.
- Lam DH. Psychosocial family intervention in schizophrenia: A review of empirical studies. *Psychol Med* 1991;21:423-441.
- Lambert T, Brennan A, Castle D, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. *J Psychiatr Pract* 2003;9:252-260.
- Landy DA. Combined use of Clozapine and electroconvulsive therapy (Case Report). *Convulsive Ther* 1991;7:218-221.
- Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. *Psychiatr Serv* 2010;61:1239-1247.
- Lara MC, Ortega SH. ¿La clinimetría o psicometría? Medición en la práctica psiquiátrica. *Salud Mental* 1995;18:32-40.
- Larsen TK, McGlashan TH, Johannessen JO, Vibe-Hansen L. First-episode schizophrenia: II. Premorbid patterns by gender. *Schizophr Bull* 1996;22:257-269.
- Lavin MR, Halligan P. ECT for comorbid obsessive-compulsive disorder and schizophrenia. *Am J Psychiatry* 1996;153:1652-1653.
- Leal MI, Sales R, Ibáñez E, Giner J, Leal C. Valoración de la sobrecarga en cuidadores informales de pacientes con esquizofrenia antes y después de un programa psicoeducativo. *Acta Española Psiquiátrica* 2008;36:63-69.

- Lebell M, Marder Re, Mintz J, Mintz IL, Tompson M, Wishing W et al. Patients, perceptions family emotional climate and outcome in schizophrenia. *Br J Psychiatry* 1993;162:751-754.
- Lee MJ, Shin YB, Sunwoo YK, Jung SH, Kim WH, Kang MH et al. Comparative Analysis of Cognitive Function in Schizophrenia with and without Obsessive Compulsive Disorder. *Psychiatr Inv* 2009;6:286-293.
- Leff J, Ballús-Creus C. Capítulo 3. Orientación familiar en las psicosis. En: Valencia, M (Compilador). *Alternativas terapéuticas para la esquizofrenia*. Editorial Herder (En Prensa); 2012.
- Leff J, Berkowitz R, Shavit N, Strachan A, Glass I, Vaughn C. A trial of family therapy versus relatives' group for schizophrenia: Two-year follow-up. *Br J Psychiatry* 1990;157:571-577.
- Leff J, Kuipers L, Berkowitz R, Sturgeon D. A controlled trial of social intervention in the families of schizophrenic patients. *Br J Psychiatry* 1985;146:594-600.
- Leff J. Family work for schizophrenia: practical application. *Acta Psychiatr Scand* 2000;407:78-82.
- Leff J. Psychiatry around the globe. A transcultural View. Gaskell. Londres. 1988.
- Leff JP, Kuipers L, Berkowitz R, Eberlein-Vries R, Surgeon D. A controlled trial of social intervention in the families of schizophrenic patients. *Br J Psychiatry* 1982;141:121-124.
- Lehman A, Buchanan R, Dickerson F, Dixon L. Evidence-based treatment for schizophrenia. *Psychiatr Clin N Am* 2003;26:939-954.
- Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. *Schizophr Bull* 2004;30:193-217.
- Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry* 2004;161:1-56.
- Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the Patient Outcomes Research Team (PORT) project. 2003;31:141-154.
- Lehman AF. Overview of best practices: current treatment guidelines and protocols for schizophrenia. Program and abstracts of the American Psychiatric Association 156th Annual Meeting; May 17-22, 2003; San Francisco, California. Abstract S28A.
- Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res* 2011;127:83-92.
- Leucht S, Arber D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? a meta-analysis of placebo-controlled trials. *Mol Psychiatry* 2008;13:1-19.
- Leucht S, Barnes T, Kissling W. Relapse Prevention in Schizophrenia with New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. *Am J Psychiatry* 2003;160:1209-1222.
- Leucht S, Burkard T, Henderson J. Physical illness and schizophrenia: a review of the literature. *Acta Psychiatr Scand* 2007;116:317-333.
- Leucht S, Corves C, Arber D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009;373:31-41.
- Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. *Cochrane Database Syst Rev*. 2007 Jul 18;(3):CD001258.
- Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. *J Clin Psychiatry* 2004;65:177-186.
- Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F et al. Meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry* 2009;166:152-163.
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophr Res* 1999;35:51-68.
- Lewine RR, Fogg L, Meltzer HY. Assessment of negative and positive symptoms in schizophrenia. *Schizophr Bull* 1983;9:368-976.
- Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. *Neuron* 2000;28:325-334.
- Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. *J Pharmacol Exp Ther*. 1988;247:661-670.
- Leysen JE, Janssen PMF, Schotte A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors. *Psychopharmacol* 1993;112:S40-S54.
- Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. *Br J Psychiatry* 1992;160:179-186.
- Lieberman R, Wallace Ch, Blackwell G. Skills Training Versus Psychosocial Occupational Therapy for Person with Persistent Schizophrenia. *Am J Psychiatry* 1998;155:1087-1091.
- Lieberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. *Psychiatr Serv* 2005;56:735-742.
- Lieberman RP. Biobehavioral therapy: Interactions between pharmacotherapy and behavior therapy in schizophrenia. En: Wykes T, Tarrier N, Lewis S. *Outcome and Innovation in Psychological Treatment of Schizophrenia*. Chichester: Edit.Wiley; 1998;179-199.
- Lieberman RP. Psychosocial Treatments for Schizophrenia. *Psychiatry* 1994;57:104-114.
- Lieberman J, Lehman A. Guía Clínica para el Tratamiento de la Esquizofrenia, Asociación Psiquiátrica Americana. 2006, Ars Médica.
- Lieberman JA, Alvir JM, Woerner M, Degreaf G, Bilder RM, Ashtari M et al. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. *Schizophr Bull* 1992;18:351-371.
- Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. *J Clin Psychiatry* 1989;50:329-338.
- Lieberman JA, Koren AR, Chakos M, Sheitman B, Woerner M, Alvir J et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. *Journal of Clinical Psychiatry* 1996;57:5-9.
- Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos MH, Nichols DE, Kraus J. Serotonergic basos of antipsychotic drug effects in schizophrenia. *Biol Psychiatry* 1998;44:1099-1117.
- Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. *Biol Psychiatry* 2001;50:884-897.
- Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. *Neuropsychopharmacol* 2003;28:995-1003.
- Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. *Am J Psychiatry*. 1994;151:1744-1752.
- Lieberman JA, Stroup S. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. *N Engl J Med* 2005;353:1209-1223.
- Lieberman JA, Stroup S. Research gaps and current research initiatives to improve the treatment of schizophrenia. Program and abstracts of the American Psychiatric Association 156th Annual Meeting; May 17-22, 2003; San Francisco, California. Abstract S28B.
- Lieberman JA, Stroup TS, Mcevoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353:1209-1223.
- Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. *J Clin Psychiatry* 1996;57:68-71.
- Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. *J Clin Psychopharmacol* 2010;30:518-525.
- Lincoln TM, Wilhelm K, Nestorciuc V. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. *Schizophr Res* 2007;96:232-245.
- Linden M, Godemann F, Gaebel W, Kopke W, Muller P, Muller-Spahn F et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. *Schizophr Bull* 2001;27:585-596.
- Lindström E, Lindström LH. A subscale for negative symptoms from the CPRS: a comparison with the SANS. *Eur Arch Psychiatry Clin Neurol* 1996;246:219-223.
- Linscott RJ, Knight RG. Potentiated automatic memory in schizotypy. *Personality and Individual Differences* 2004;37:1503-1517.
- Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. *Am J Psychiatry* 1992;149:83-88.
- Loewenthal KM, Cinnirella M. Beliefs about the efficacy of religious, medical and psychotherapeutic interventions for depression and schizophrenia among women from different cultural-religious groups in Great Britain. *Transcult Psychiatry* 1999;36:491-504.
- Lopez M, Laviana M. Rehabilitación, apoyo social y atención comunitaria a personas con trastorno mental grave. Propuesta desde Andalucía. *Rev Asoc Esp Neuropsiq* 2007;27:187-223.
- Loth AK, Pataky C. Childhood-onset schizophrenia. <http://emedicine.medscape.com/article/914840-overview>
- Lóyzaga C, Nicolini H, Apiquián R, Fresán A. Fenómeno Esquizo-obsesivo en pacientes con diagnóstico de esquizofrenia: prevalencia y variables sociodemográficas. *Psiquiatría y Salud Integral* 2003;3:48-55.
- Lóyzaga C, Nicolini H, Apiquián R, Fresán A. Una aproximación al fenómeno esquizo-obsesivo. *Salud Mental* 2002;25:12-18.
- Lóyzaga C. Evaluación del Fenómeno esquizo-obsesivo en pacientes con diagnósticos de esquizofrenia y trastorno obsesivo-compulsivo. Tesis para obtener el grado de Maestra en Ciencias. UNAM. INP. Noviembre 2001.
- MacBeth A, Gumley A. Premorbid adjustment, symptom development and quality of life in first episode psychosis: a systematic review and critical reappraisal. *Acta Psychiatr Scand* 2008;117:85-99.
- Macêdo DS, Oliveira GV, Gomes PX, Araújo FY, Souza CM, Vasconcelos SM et al. Vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms. *Behav Pharmacol* 2011;22:674-680.
- Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants: a review of the literature and an analysis of spontaneous reports. *Ann Clin Psychiatry* 2010;22:148-156.
- Magaña S, García J, Hernández M, Cortez R. Psychological distress among Latino family caregivers of adult with Schizophrenia: The roles of burden and stigma. *Psychiatr Serv* 2007;58:378-384.
- Magliano L, Fiorillo A, De Rosa C, Maj M and the National Mental Health Project Working Group. Family burden and social network in schizophrenia vs. physical diseases: preliminary results from an Italian national Study. *Acta Psychiatr Scand* 2006;113:60-63.

- Magliano L, Fiorillo A, Malangone C. Patient functioning and family burden in a controlled, real-world trial of family. *Psychiatr Serv* 2006;57:1784-1791.
- Magliano L, Fiorillo A. Psychoeducational family interventions for schizophrenia in the last decade: from explanatory to pragmatic trials. *Epidemiol Psychiatr Soc* 2007;16:22-34.
- Malaspina D, Harlap S, Fennig S, Herman D, Nahon D, Feldman D et al. Advancing paternal age and the risk of schizophrenia. *Arch Gen Psychiatry* 2001;58:361-367.
- Malla A, Lal S, Vracotas NC, Goldberg K, Joobar R. Early intervention in psychosis: specialized intervention and early case identification. *L'Encephale* 2010;36:S38-S45.
- Malla A, Norman R, Schmitz N, Manchanda R, Bechard-Evans L, Takhar J et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. *Psychol Med* 2006;36:649-658.
- Malla A, Williams R, Kopala L. Outcome on quality of life in a Canadian national sample of patients with schizophrenia and related psychotic disorders. *Acta Psychiatr Scand* 2006;113:22-28.
- Malla AK, Norman RM, Manchanda R, Townsend L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. *Psychol Med* 2002;32:1109-1119.
- Malm U, Dencker S. Evaluation of the Quality of Life the Schizophrenic Outpatient: A Checklist. *Schizophr Bull* 1981;7:477-486.
- Malm U, Ivarsson B, Allebeck P, Falloon IR. Integrated care in schizophrenia: a 2-year randomized controlled study of two community-based treatment programs. *Acta Psychiatr Scand* 2003;107:415-423.
- Malm U. Group therapy. En: Herz MI, Keith SJ, Docherty JP (eds). *Handbook of Schizophrenia*, Vol 4 Psychosocial treatment of Schizophrenia. Amsterdam: Elsevier;1990;191-211.
- Mandel MR, Welch CA, Mieske M. Prediction of response to ECT in tricyclic-intolerant of tricyclic-resistant depressed patients. *Mc Lean Hosp J* 1977;2:203-209.
- Mann JJ. The medical management of depression. *N Engl J Med* 2005;353:1819-1834.
- Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. *Schizophr Res* 2012;134(2-3):180-186.
- March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. *Am J Psychiatry* 2005;162:836-846.
- Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. *Am J Psychiatry* 1995;152:959.
- Marder SR. Integrating pharmacological and psychosocial treatments for schizophrenia. *Acta Psychiatr Scand* 2000;102(s407):87-90.
- Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004;161:1334-1349.
- Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 1994;151:825-835.
- Margolese HC, Chouinard G, Kolivakis TT. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. *Can J Psychiatry* 2005;50:541-547.
- Mari JJ, Streiner DL. An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. *Psychol Med* 1994;24:565-578.
- Marian S, Peterson K, Carson S, Fu R, Thakurta S. Drug Class Review Atypical Antipsychotic Drugs: Final Update 3 Report July 2010.
- Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD000050. DOI:10.1002/14651858.CD000050.
- Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. *Arch Gen Psychiatry* 2005;62:975-983.
- Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998 (2):CD001089.
- Marshall M, Rathbone J. Early intervention for psychosis. *Schizophr Bull* 2011;37:1111-1114.
- Martin JL, Pérez V, Sacristán M et al. Meta-analysis of drop-out rates in randomized clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. *Eur Psychiatry* 2006;21:11-20.
- Martinot JL, Huret JD, Mazoyer B. Striatal D2 dopaminergic receptors assessed with Positron Emission Tomography and (76 Br) bromospiperone in untreated schizophrenic patients. *Am J Psychiatry* 1990;147:44-50.
- Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. *Psychopharmacol* 1996;124:154-158.
- Martins C, de Lemos AI, Bebbington PB. A Portuguese/Brazilian study of Expressed Emotion. *Soc Psychiatr Epidemiol* 1992;27:22-27.
- Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. *Prim Care Companion J Clin Psychiatry* 2009;11:147-154.
- Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. *Drugs* 2011;71:179-208.
- Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. *Schizophr Res* 2004;71:227-237.
- Mathalon D, Sullivan E, Lim K, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: A longitudinal magnetic resonance imaging study. *Arch Gen Psychiatry* 2001;58:148-157.
- McCabe C, Dixon S. Testing the validity of cost effectiveness models. *Pharmacoeconomics* 2000;17:501-513.
- McCarthy B. The role of relatives. In: Lavender A, Holloway F (eds). *Community care in practice*. Wiley, Chichester 1988.
- McCrone P, Strathee G. Needs not diagnosis: towards a more rational approach to community mental health resourcing in Britain. *Int J Soc Psychiatry* 1994;40:79-86.
- McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. *Br J Psychiatry* 2006;189:433-440.
- McDonald A, Carter C, Kerns J, Ursu S, Barch D, Holmes A, Stenger V, Cohen J. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. *Am J Psychiatry* 2005;162:475-484.
- McEvoy J, Freudenreich O, McGree M. Clozapine decreases smoking in patients with chronic schizophrenia. *Biol Psychiatry* 1995;37:550-552.
- McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. *Arch Gen Psychiatry* 1991;48:739-745.
- McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006;163:600-610.
- McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. *J Clin Psychiatry* 1999;60:3-80.
- McEvoy JP. Antipsychotic drugs. In: Squire LR (ed). *Encyclopedia of neuroscience* Vol 1. Oxford (GB): Academic Press; 2009:487-492.
- McFarlane W, Link B, Dushay R, Marchal J, Crilly J. Psychoeducational multiple family groups: Four-year relapse outcome in schizophrenia. *Fam Process* 1995;34:127-144.
- McGlashan TH, Fenton WS. The positive-negative distinction in schizophrenia. Review of natural history validators. *Arch Gen Psychiatry* 1992;49:63-72.
- McGlashan TH. A selective review of recent North American long-term follow up studies of schizophrenia. *Schizophr Bull* 1988;14:515-542.
- McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? *Biol Psychiatry* 1999;46:899-907.
- McGlashan TH. Early detection and intervention in psychosis: An ethical paradigm shift. *Br J Psychiatry* 2005;48:s113-s115.
- McGorry P. International clinical practice guidelines for early psychosis. *Br J Psychiatry* 2005;187(Suppl):s120-s124. Doi:10.1192/bjp.187.48.s120.
- McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. *World Psychiatry* 2008;7:148-156.
- McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. *J Clin Psychiatry* 2009;70:1206-1212.
- McGorry PD. Evaluating the importance of reducing the duration of untreated psychosis. *Aust N Z J Psychiatry* 2000;34:S145-S197.
- McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Medicine* 2004;2:13.
- McGurk R, Mueser KT, DeRosa TJ, Wolfe R. Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. *Schizophr Bull* 2009;35:319-335.
- McGurk SR, Twamley EW, Sitzler DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry* 2007;164:1791-1802.
- McKay DR, Tennant CC. Is de grass greener? The link between cannabis and psychosis. *Med J Aust* 2000;172:284-286.
- McKenna PJ, Lund CE, Mortimer AM, Biggins CA. Motor, volitional and behavioral disorders in schizophrenia 2: The "conflict of paradigms" hypothesis. *Br J Psychiatry* 1991;158:328-336.
- McNulty S, Duncan L, Semple M, Jackson G, Pelosi A. Care needs of elderly people with schizophrenia. Assessment of an epidemiologically defined cohort in Scotland. *Br J Psychiatry* 2003;182:241-247.
- Meats P. Quetiapine: an effective and well tolerated atypical antipsychotic. *Int J Psychiatric Clin Prac* 1997;1:231-239.
- Medina E. Aproximaciones al chamanismo y neochamanismo latinoamericano: presencia actual de algunas manifestaciones. *Memorias del 3er congreso internacional de GLADET*. Tuxtla Gutiérrez, Chiapas. 2012.
- Medina MA, Borges G, Lara MC. Prevalencia de trastornos mentales y uso de servicios: Resultados de la encuesta nacional de epidemiología psiquiátrica en México. *Salud Mental* 2003;26:1-16.
- Mednick SA, Machon RA, Huttunen MO, Bonnett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. *Arch Gen Psychiatry* 1988;5:189-192.
- Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. *J Clin Psychopharmacol* 2001;21:389-397.
- Mehler-Wex C, Kolch M, Kirchheiner J, Antony G, Fegert JM, Gerlach M. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. *J Child Adol Psychiatry Mental Health* 2009;3:14.
- Melle I, Haahr U, Friis S. Reducing the duration of untreated first-episode psychosis-effects on baseline social functioning and quality of life. *Acta Psychiatr Scand* 2005;112:469-473.
- Meltzer HY. Decreasing suicide in schizophrenia. *Psychiatric Times* 2001;18:1-5.
- Meltzer HY, Baldessarini RJ. Reducing high risk for suicide in schizophrenia and affective disorders. *J Clin Psychiatry* 2003;64:1122-1129.

- Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. *Psychiatry Res* 2010;177:286-293.
- Meltzer HY. Duration of a clozapine trial on neuroleptic-resistant schizophrenia. *Arch Gen Psychiatry* 1989;46:672.
- Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. *Curr Psychiatry Rep* 2002;4:279-283.
- Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. *Curr Med Res Opin* 1997;14:1-20.
- Meltzer JY, Cola P, Way L, Thompson PA, Bastani B, Davies MA et al. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. *Am J Psychiatry* 1993;150:1630-1638.
- Meltzer MI. Introduction of Health Economics for physicians. *Health Economics Quintet*. Lancet 2001;358:993-998.
- Merrill DB, Ahmari SE, Bradford JM et al. Myocarditis during clozapine treatment. *Am J Psychiatry* 2006;163:204-208.
- Meynert T. Amentia, die Verwirrtheit. *Jahrbuch der Psychiatrie* (Vienna) 1889;9:1-112.
- Mezzich JE, Kleinman A, Fabrega H, Parron DL. Culture and Psychiatric Diagnosis. A DSM-IV Perspective. *Am Psych Press* 1996.
- Miles CP. Conditions Predisposing to suicide: a review. *J Nervous Mental Disorders* 1977;164:231-246.
- Miles P, Ho B-C, Arndt S, Andreasen N. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first episode study with 7-year follow-up. *Am J Psychiatry* 2005;162:495-506.
- Miller AL, Crismon L, Rush J, Chiles J, Kashner M, Toprac M et al. The Texas Medication Algorithm Project: Clinical Results for Schizophrenia. *Schizophr Bull* 2004;30:627-647.
- Miller BJ. A review of second-generation antipsychotic discontinuation in first-episode psychosis. *J Psychiatr Pract* 2008;14:289-300.
- Miller CH, Fleischacker WW. Managing antipsychotic-induced acute and chronic akathisia. *Drug Saf* 2000;22:73-81.
- Miller CH, Mohr F, Umbricht D, Woerner M, Fleischacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. *J Clin Psychiatry* 1998;59:69-75.
- Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W et al. Prodromal Assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive Validity, Interrater Reliability, and Training to Reliability. *Schizophr Bull* 2003;29:703-715.
- Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM et al. Symptom assessment in schizophrenic prodromal states. *Psychiatr Q* 1999;70:273-287.
- Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 Functional Neuroimaging Studies of Executive Function in Schizophrenia. *Arch Gen Psychiatry* 2009;66:811-822.
- Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. *Biol Psychiatry* 2004;55:1013-1022.
- Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. *Am J Psychiatry* 1997;154:1170.
- Misra LK, Erpenbach JE, Hamlyn H, Fuller WC. Quetiapine: a new atypical antipsychotic. *D J Med* 1998;51:189-193.
- Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Mol Psychiatry* 2004;10:79-104.
- Mojtabai R, Lavelle J, Gibson PJ, Sohler NL, Craig TJ, Carlson GA et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. *Psychiatr Serv* 2002;53:337-339.
- Mojtabai R, Nicholson R, Carpenter B. Role of Psychosocial Treatments in Management of Schizophrenia: A Meta-Analytic Review of Controlled Outcome Studies. *Schizophr Bull* 1998;24:569-587.
- Molina Fray Alonso. Vocabulario en lengua castellana y mexicana y mexicana castellana. Edición Facsímil. México: Ed. Porrúa; 1970.
- Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. *Drugs* 2007;67:1541-1566.
- Möller HJ. The negative component in schizophrenia. *Acta Psychiatr Scand* 1995;388:11-14.
- Montout C, Casadebaig F, Lagnaoui R. Neuroleptics and mortality in Schizophrenia, prospective analysis of deaths in french cohort of schizophrenic patients. *Schizophr Res* 2002;57:147-157.
- Morel BA. *Traité des maladies mentales*. Masson: Paris. 1860.
- Morgenstern H, Glazer WM, Gibowski LD. Predictors of tardive dyskinesia: Results of a cross sectional study in an outpatient population. *J Chron Dis*. 1987;40:319-327.
- Moriana JA, Alarcón E, Herruzo J. Capítulo 4. Rehabilitación psicosocial para esquizofrenia y trastornos mentales graves en contextos domiciliarios. En: Valencia M (Compilador). *Alternativas terapéuticas para la esquizofrenia*. Editorial Herder (En Prensa); 2012.
- Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000;101:323-329.
- Moser LL, Deluca NL, Bond GR, Rollins AL. Implementing evidence-based psychosocial practices: lessons learned from statewide implementation of two practices. *CNS Spectr* 2004;9:926-936.
- Mould QJ, Contreras HI, Verdusco W, Mejía AJ, Garduño EJ. Análisis de simulación de costo-efectividad en el tratamiento de la esquizofrenia en el Instituto Mexicano del Seguro Social. Evaluación de antipsicóticos típicos y atípicos. *Rev Psiquiatr Salud Ment* (Barc) 2009;2:108-118.
- Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. *Schizophr Bull* 1998;24:37-74.
- Mueser KT, Corrigan PW, Hilton D, Tanzman B, Schaub A, Gingeric S. Illness management and recovery: a review of the research. *Psychiatr Serv* 2002;53:1272-1284.
- Mueser KT, Lu W, Rosenberg SD, Wolfe R. The trauma of psychosis: posttraumatic stress disorder and recent onset psychosis. *Schizophr Res* 2010;116:217-227.
- Mueser KT, Salyers MP, Mueser PR. A prospective analysis of work in schizophrenia. *Schizophr Bull* 2001;27:281-296.
- Muñoz HO, Garduño EJ, Pérez CR. Higiya y Panacea en la salud y la sociedad. Los sistemas de salud, un producto de la evolución social. *Rev Med IMSS* 2005;43:411-417.
- Murphy HBM, Raman AC. The chronicity of schizophrenia in indigenous tropical people. *Br J Psychiatry* 1971;118:489-497.
- Murphy HBM. *Comparative Psychiatry: The International and Intercultural Distribution of Mental Illness*. Berlin: Springer, 1982.
- Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? *BMJ* 1987;295:681.
- Murray RM, O'Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the classification of schizophrenia. *Schizophr Bull* 1992;18:319-332.
- Nagai M, Kishi K, Kato S. Insular cortex and neuropsychiatric disorders: a review of recent literature. *Eur Psychiatry* 2007;22:387-394.
- Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdeken M et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. *Neuropsychopharmacology* 2010;35:2072-2082.
- National Collaborating Centre for Mental Health (UK). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet]. Leicester (UK): British Psychological Society; 2009 Mar. (NICE Clinical Guidelines, No. 82.) 6. Pharmacological interventions in the treatment and management of schizophrenia. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK11670>
- Ndetei DM, Vaher A. Frequency and clinical significance of delusions across cultures. *Acta Psychiatrica Scand* 1984;70:73-76.
- Neimeyer RA, Mahoney MJ. *Constructivism in Psychotherapy*. Am Psychol Press, Washington, DC. 1995.
- Nestler EJ. An emerging pathophysiology. *Nature* 1997;358:578-579.
- Nestor PG, Kubicki M, Niznikiewicz M, Gurrera RJ, McCarley RW, Shenton ME. Neuro-psychological disturbance in schizophrenia: a diffusion tensor imaging study. *Neuropsychology* 2008;22:246-254.
- Nestor PG, Kubicki M, Spencer KM, Niznikiewicz M, McCarley RW, Shenton ME. Attentional networks and cingulum bundle in chronic schizophrenia. *Schizophr Res* 2007;90:308-315.
- Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. *J Clin Psychiatry* 2007;68:20-27.
- Newton R, Hustig H, Lakshmana R, Lee J, Motamarri B, Norrie P et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia. *Curr Med Res Opin* 2012;28:559-567.
- Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. *Acta Psychiatr Scand* 2007;116:36-46.
- NICE. Guidelines for antipsychotic medication switches. NHS 2009.
- NICE. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Nice Technology Appraisal Guidance No. 43. 2012 London.
- Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. *Acta Psychiatr Scand* 2011;123:411-422.
- Nielsen J, Toft E. The spectrum of cardiovascular disease in patients with schizophrenia. En: Meyer JM, Nasrallah HA (eds). *Medical Illness and Schizophrenia* 2nd edition. American Psychiatric Publishing; 2009:169-202.
- Niendam TA, Jalbrzikowski M, Bearden CE. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. *Neuropsychol Rev* 2009;19:280-293.
- Niznikiewicz M, Sentón M, Voglmaier M, Nestor P, Dickey Ch, Frumin M et al. Semantic dysfunction in women with schizotypal personality disorder. *Am J Psychiatry* 2009;166:1767-1774.
- Nobler MS, Sackeim HA, Solomou M, Lubner B, Devanand DP, Prudic J. EEG manifestations during ECT: Effects of electrode placement and stimulus intensity. *Biol Psychiatry* 1993;34:321-330.
- Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. *CNS Neurosci Ther* 2011;17:97-103.
- Nordström AL, Nyberg S, Olsson H, Farde L. Positron emission tomography finding of a high striatal D2 occupancy in olanzapine-treated patients. *Arch Gen Psychiatry* 1998;55:283-284.
- Nordström AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naïve schizophrenic patients revealed by Positron Emission Tomography and (11 C) N-methylspiperone. *Psychiatr Res Neuroimaging* 1995;61:67-83.
- Nordström AL, Farde L, Nyberg S. D1, D2 and 5HT2 receptor occupancy in relation to clozapine serum concentration: A PET study schizophrenic patients. *Am J Psychiatry* 1995;152:1444-1449.
- Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. *Psychol Med* 2001;31:381-400.

- Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. *Eur Psychiatry* 2002;17:148-154.
- Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. *J Clin Psychopharmacol*. 2010;30:531-540.
- Nuechterlein KH, Robbins TW, Eilat H. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference. *Schizophr Bull* 2005;31(4):870-874.
- Nussbaum AM, Stroup TS. Paliperidone for treatment of schizophrenia. *Schizophr Bull*. 2008;34:419-422.
- Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. *Cochrane Database Syst Rev* 2012;6:CD008296.
- Nyhus A, Faries D, Ascher-Svanum H, Stauffer V, Kinon B. Predictors of switching antipsychotic medications in the treatment of schizophrenia *BMC Psychiatry* 2010;10:75.
- O'Donoghue B, Schäfer MR, Becker J, Papageorgiou K, Amminger GP. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. *Early Interv Psychiatry*. 2013 Aug 22. Doi:10.1111/eip.12083. [Epub ahead of print].
- O'Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. *J Neuropsychiatry Clin Neurosci* 2000;12:4-15.
- Obiols JE, Salvador L, Humbert M, Obiols J. Escala para la evaluación del Pensamiento, Lenguaje y Comunicación, Universidad de Barcelona, 1985.
- Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. *Int J Clin Pract* 2007;61:1979-1988.
- Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. *Acta Psychiatr Scand* 2000;(Suppl):83-86.
- Oka M, Otsuka K, Yokohama N, Mint J, Hocino K, Niwa S, Liberman P. An evaluation of a Irbid occupational therapy and supported employment program in Japan for persons with schizophrenia. *American Journal of Occupational Therapy* 2004;58:466-475.
- Olsson M, West JC, Wilk JE, Marcus S. Factors affecting the effectiveness of clinical decisions in treating schizophrenia. Program and abstracts of the American Psychiatric Association 156th Annual Meeting, May 17-22, 2003; San Francisco, California. Abstract S28C.
- Olin SC, Mednick SA. Risk factors of psychosis: identifying vulnerable populations pre-morbidly. *Schizophr Bull* 1996;22(2):223-240.
- OMS http://www.who.int/mental_health/main
- OMS: Informe sobre la salud en el mundo 2001, Salud mental: nuevos conocimientos nuevas esperanzas. Ginebra Suiza.
- OMS: CIE 10. Trastornos mentales y del comportamiento. Descripción clínica y pautas para el diagnóstico. OMS, España; 1992.
- Oosthuizen P, Emsley RA, Keyter N, Niehaus DJ, Koen L. Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country. *Acta Psychiatr Scand* 2005;111:214-219.
- Opler M. Culture and Mental Health. New York: Macmillan, 1959.
- Organization WH. The International Classification of Diseases 11th Revision. Geneva 2012 [29-Sep-2012] <http://www.who.int/classifications/icd/revision/en/index.html>
- Ortega-Soto HA, Valencia CM. El tratamiento farmacológico de la esquizofrenia. En: de Ortega H, Valencia M (eds). Esquizofrenia: Estado actual y perspectivas. Colección de libros del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñoz, México, D.F.; 2001;349-398.
- Ortega-Soto HA, Brunner E, de la Torre MP, García Marín J. Inicio de tratamiento con decanoato de haloperidol en pacientes con esquizofrenia. *Psiquiatría y Salud Integral* 1995;11:79-83.
- Ortega-Soto HA, Gracia S, Imaz B, Pacheco J, Brunner E, Apiquian R, De la Torre M. Validez y Reproducibilidad de una escala para evaluar la depresión en pacientes esquizofrénicos. *Salud Mental* 1994;17:7-14.
- Ortega-Soto HA, Rodríguez MS. Diagnóstico y Clasificación. En: Ortega-Soto HA, Valencia CM (eds). Esquizofrenia. Estado actual y perspectivas. Publicaciones del Instituto Nacional de Psiquiatría Ramón de la Fuente. 2001;33-60.
- Ortega-Soto HA. Clozapina. Estado actual del conocimiento. *Salud Mental* 1993;16:1-2.
- Ortega-Soto HA. El síndrome extrapiramidal con el uso de psicofármacos. *Psiquiatría (Méx)* 1985;1:141-150.
- Ortega-Soto HA. Mecanismos de acción de los Neurolepticos. *Psiquiatría (Méx)* 1986;2:150-160.
- Ortega-Soto HA. Niveles séricos de Neurolepticos. *Salud Mental* 1986;9:30-42.
- Ortega-Soto HA. Tratamiento farmacológico de la esquizofrenia. *Psicología Iberoamericana* 1998;6:4-17.
- Ortega-Soto HA, Jasso A, Cecaña G, Hernández CA. La validez y reproducibilidad de dos escalas para evaluar los síntomas extrapiramidales inducidos por neurolepticos. *Salud Mental* 1991;14:1-5.
- Ortega-Soto HA, Paéz AF, Fernández SA et al. El efecto terapéutico de las dosis umbrales de haloperidol: Resultados preliminares. *Anales del Instituto Mexicana de Psiquiatría*. 1991;2:30-34.
- Ortega-Soto HA, Valencia CM (eds). Esquizofrenia. Estado actual y perspectivas. Publicaciones del Instituto Nacional de Psiquiatría Ramón de la Fuente 2001;358-377.
- Otani K, Kondo T, Kaneko S. Steady-state serum kinetics of zotepine. *Human Psychopharmacol* 1992;7:331-336.
- Oulis PG, Mavreas VG, Mamounas JM, Stefanis CN. Clinical characteristics of auditory hallucinations. *Acta Psychiatr Scand* 1995;92:97-102.
- Owen C, Tarantello C, Jones M, Tennant C. Repetitively violent patients in psychiatric units. *Psychiatr Serv* 1998;49:1458-1461.
- Owen MJ, Craddock N, Jablensky A. The genetic deconstruction of psychosis. *Schizophr Bull* 2007;33:905-911.
- Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2010;34:401-405.
- Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. *Am J Psychiatry* 2004;161:53-58.
- Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. *Arch Gen Psychiatry* 2005;62(3):247-253.
- Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. *Arch Med Res* 2002;33:572-580.
- Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2011;35:218-226.
- Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. *Ther Adv Psychopharmacol* 2013;3:33-51.
- Parellada E. Clinical experience and management considerations with long-acting risperidone. *Curr Med Res Opin* 2006;22:241-255.
- Parker S, French P. Report on Early Detection and Intervention for Young People at Risk of Psychosis. 2007 <http://tinyurl.com/worzyh>
- Patel NH, Vyas NS, Puri BK, Nijran KS, Al-Nahhas A. Positron emission tomography in schizophrenia: a new perspective. *J Nucl Med* 2010;51:511-520.
- Patel V, Flisher AJ, Hetrick S, McGorry P. Mental health of young people: a global public-health challenge. *Lancet* 2007;369:1302-1313.
- Patterson TL, Bucardo J, McKibbin CL. Development and pilot testing of a new psychosocial intervention for older Latinos with chronic psychosis. *Schizophr Bull* 2005;31:922-930.
- Pauker SG, Kassirer JP. Medical progress-decision analysis. *N Engl J Med* 1978; 316:250-258.
- Paul SM, Extein I, Calil HM et al. Use of ECT with treatment resistant depressed patients at the National Institute of Mental Health. *Am J Psychiatry* 1981;138:486-489.
- Payne J, Malla A, Norman R, Windell D, Nicole B. Status of first-episode psychosis patients presenting for routine care in a defined catchment area. *Can J Psychiatry* 2006;51:42-47.
- Paz CR, Amarilla AC. Las psicosis cicloides: una propuesta terapéutica. *Psicomundo*. Consultado el: 24-12-05, en: <http://www.herrerros.com.ar/melanco/paz.htm>
- Pedersen D. Estigma y exclusión social en la enfermedad mental: apuntes para el análisis e investigación. *Revista de Psiquiatría y Salud Mental "Hermilio Valdizán"* 2005;6:3-14.
- Pekkala E, Merinder L. Psychoeducation for schizophrenia. *Cochrane Database Syst Rev* 2002;2. Doi:10.1002/14651858. CD002831.
- Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. *Am J Psychiatry* 1996;153:607-617.
- Peralta V, Cuesta MJ. Subjective experiences in schizophrenia: a critical review. *Compr Psychiatry* 1994;35:198-204.
- Peralta V, Cuesta MJ, de León J. Formal Thought Disorder in Schizophrenia: A Factor Analytic Study. *Comprehensive Psychiatry* 1992;33:105-110.
- Peralta V, Cuesta MJ, Martínez-Larrea A, Serrano JF. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naïve patients before and after treatment. *Am J Psychiatry* 2000;157(9):1461-1466.
- Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. *Acta Psychiatr Scand* 1997;95:464-468.
- Pérez DA. Funcionamiento Psicosocial de personas con esquizofrenia que participan en Programas de Rehabilitación Psicosocial ejecutados por COSAM (Centros Comunitarios de Salud Mental) de la Zona Occidente (Región Metropolitana). Investigación presentada a la Escuela de Psicología de la Pontificia Universidad Católica de Chile para optar al grado académico de Magister en Psicología Mención Psicología Social-Comunitaria. Informe devolutivo. Ministerio de Salud de Chile. Departamento de Salud Mental. Julio, 2009.
- Perez I, Crespo F, Martinez G. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. *Schizophr Res* 2008;99:13-22.
- Pérez-Rincón H. Le Mexique. pp. 563-572. En: Postel & Quétel. Histoire de la Psychiatrie. 1994;647.
- Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. *Am J Psychiatry* 2005;162:1785-1804.
- Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. *J Clin Psychiatry* 2008;69:106-113.
- Perlick DA, Rosenheck RA, Kaczynski R, Swartz M, Canive JM, Lieberman J. Components and Correlates of Family Burden in Schizophrenia. *Psychiatr Serv* 2006;57:1117-1125.
- Perlstein WM, Dixit NK, Carter CS, Noll DC, Cohen JD. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. *Biol Psychiatry* 2003;53:25-38.

- Perrault GH, Depoortere R, Morel E, Sanger OJ, Scatton B. Psychopharmacological profile amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. *J. Pharmacol Exp Ther* 1997;280:73-82.
- Plammatter M, Junghans U, Brenner H. Efficacy of Psychological Therapy in Schizophrenia: Conclusions from Meta-analyses. *Schizophr Bull* 2006;32:564-580.
- Phutane VH, Thirithalli J, Muralidharan K, Naveen Kumar C, Keshav Kumar J, Gangadhar BN. Double-blind randomized controlled study showing symptomatic and cognitive superiority of bifrontal over bitemporal electrode placement during electroconvulsive therapy for schizophrenia. *Brain Stimul* 2013;6(2):210-217. Doi:10.1016/j.brs.2012.04.002. Epub 2012 Apr 23.
- Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapoport M. Clinical and biologic response to clozapine in patients with schizophrenia. *Archives of General Psychiatry* 1992;49:345-353.
- Pilling S, Bebbington P, Kuipers E, Garety E, Geddes J, Orbach G et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. *Psychol Med* 2002;32:763-782.
- Pilling S, Bebbington P, Kuipers E, Garety E, Geddes J, Orbach G et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. *Psychol Med* 2002;32:783-791.
- Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Metoclopramide: a review of its pharmacological properties and clinical use. *Drugs* 1976;12:81-131.
- Platt S, Weyman A, Hirsh S, Hewett S. The Social Behaviour Assessment Schedule (Sbas): Rationale Contents, Soring And Reliability of A New Interview Schedule. *Social Psychiatry* 1980;15:43-55.
- Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost-effectiveness analyses of antipsychotic use. *Am J Psychiatry* 2006;163:2047-2056.
- Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). *Pharmacoeconomic Drug Saf* 2009;18:512-518.
- Pompili M, Tondo I, Baldessarini RJ. Suicidal risk emerging during antidepressant treatment recognition and intervention. *Clin Neuropsychiatry* 2005;2:66-72.
- Pompili M, Lester D, Innamorati M, Tatarelli R, Girardi P. Assessment and treatment of suicide risk in schizophrenia. *Exp Rev Neurother* 2008;8:51-74.
- Popović I, Ravančić D, Popović V, Vladijević S, Stanojević A, Stojanović M. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. *Psychiatr Danub* 2011;23:384-388.
- Portwich P, Barocka A. The concept of negative and positive symptoms in a historical perspective. *Fortschr Neurol Psychiatr* 1999;67(10):448-455.
- Potkin SG, Alphas L, Hsu C, Krishnan KR, Anand R, Young FK, Meltzer H, Green A. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. *Biol Psychiatry* 2003;54:444-452.
- Poyurovsky M, Fuchs C, Weizman A. Obsessive-Compulsive disorder in patients with first episode schizophrenia. *American Journal Psychiatry*. 1999;156:1998-2000.
- Poyurovsky M, Isakov V, Hromnikov S. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. *International Clinical Psychopharmacology* 1999;14(2):95-100.
- Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: Clinical characteristics and treatment. *CNS Drugs* 2004;18:989-1010.
- Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association 2004. Disponible en: http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete- Feb04.pdf
- Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of national institute of Mental Health - psychopharmacology research branch collaborative study group. *Arch Gen Psychiatry* 1968;18:482-495.
- Prior T, Baker G. Interactions between the cytochrome P450 system and the second-generation antipsychotics. *J Psychiatry Neurosci* 2003;28:99-112.
- Prudic J, Devanand DP, Sackeim HA, Decina P, Kerr B. Relative response of endogenous and non-endogenous symptoms to electroconvulsive therapy. *J. Affective Disord.* 1989;16:59-64.
- Pycocck CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. *Nature* 1980;286:74-77.
- Quiroga H, Rodríguez M, Cardenas G, Vite A, Mata A, Molina J et al. Programas de tratamiento psicosocial para la rehabilitación del paciente mental crónico hospitalizado en México: Descripción, resultados y perspectivas. *Rev Mex Psicología* 1986;3(1):44-58.
- Quiroga H. La rehabilitación del paciente mental crónico hospitalizado. I Reunión sobre Investigación y Enseñanza. Instituto Mexicano de Psiquiatría 1982;203:21-25.
- Rabinovitch M, Bechard-Evans L, Schmitz N, Joobar R, Malla A. Early predictors of non-adherence to antipsychotic therapy in first-episode psychosis. *Can J Psychiatry* 2009;54:28-35.
- Raguram R, Raghu T, Vounatsou P, Weiss M. Schizophrenia and the cultural epidemiology of stigma in Bangalore, India. *J Nerv Ment Dis* 2004;192:734-744.
- Rajj TT, Valkonen-Korhonen M, Holi M, Therman S, Lehtonen J, Hari R. Reality of auditory verbal hallucinations. *Brain* 2009;132:2994-3001.
- Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. *Br J Psychiatry* 2009;195:286-293.
- Rami L, Bernardo M, Valdes M, Boget T, Portella MJ et al. Absence of Additional Cognitive Impairment in Schizophrenia Patients During Maintenance Electroconvulsive Therapy. *Schizophr Bull* 2004;30(1):185-189.
- Ramirez J, Garnica R, Boll MC, Montes S, Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. *Schizophr Res* 2004;68:357-361.
- Randolph E, Spencer E, Glynn S, Paz G, Shaner A, Strachan A et al. Behavioral family management in schizophrenia: Outcome of a clinic-based intervention. *Br J Psychiatry* 1994;164:501-506.
- Rapoport JL, Giedd JN, Blumenthal J, Hamburger S, Jeffries N, Fernandez T. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. *Arch Gen Psychiatry* 1999;56:649-654.
- Rascón D, Valencia M. Los Factores Familiares en la Esquizofrenia Cap. VIII. En: Esquizofrenia estado actual y perspectivas. Colección del Instituto Nacional de Psiquiatría Ramón de la Fuente. 2001;pp 301-348.
- Rascón D, Díaz M LR, López J JL. Consecuencias familiares por el cuidado del paciente esquizofrénico. En: Jiménez Guillén R. (Compilador). Familia: una construcción social. Universidad Autónoma de Tlaxcala, Depto de Educación Especializada, Centro Universitario de Estudios para la Familia, 1998;pp 413-429.
- Rascón GD, Díaz ML Rosa, Valencia M. Relación entre la emoción expresada y la opinión afectiva de familiares y pacientes esquizofrénicos. *Rev Psicología Iberoamericana Nueva Epoca* 1998;6(4):56-65.
- Rascón G ML. Estudio de familias de pacientes con esquizofrenia. Tesis de doctorado en psicología por investigación; Facultad de Psicología. Universidad Nacional Autónoma de México, Abril 2001.
- Rascón ML, Alcántara H, Domínguez T, Casanova L. Las necesidades clínicas y sociales de familiares de personas con esquizofrenia. En: Peña Saint Martín F, León Parra B (Coord.). Medicina Social en México 1. Experiencias, subjetividad y salud.; Ed. EON; ISBN: 978-607-7519-87-4; 2010;pp. 89-104.
- Rascón ML, Alcántara H. La familia como instrumento para reducir riesgos en la esquizofrenia Cap. 7. En: Valencia, M (Compilador). Alternativas terapéuticas para la esquizofrenia. Editorial Herder (En prensa); 2012.
- Rascón ML, Cámara G, García S, Alcántara H, Sampedro A, Casanova L. Beneficios del Curso Familia a Familia, NAMI (Cartel). *Voz Pro Salud Mental y National Alliance on Mental Illness. Congreso APM, Acapulco Gro.* 2009.
- Rascón ML, Caraveo J, Valencia M. Trastornos emocionales, físicos y psiquiátricos en los familiares de pacientes con esquizofrenia en México. *Rev Invest Clin* 2010;62:509-515.
- Rascón ML, Gutiérrez LM, Valencia CM, Rodríguez VS. Percepción de los familiares del intento y la ideación suicida en sus parientes con esquizofrenia. *Rev Salud Mental* 2004;27:44-52.
- Rascón-Gasca ML, Díaz-Martínez RL, Ramos-Lira L. La violencia doméstica en familiares de pacientes con esquizofrenia. *Gac Méd Méx* 2003;139 (4):371-376.
- Raskin A, Pelchat R, Sood R, Alphas LD, Levine J. Negative Symptom Assessment of Chronic Schizophrenia Patients. *Schizophr Bull* 1993;19:627-635.
- Ratzoni G, Gothelf D, Brand-Gothelf D, Reidman J, Kikinzon I, Gal G. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. *J Am Acad Child Adolesc Psychiatry* 2002;41:337-343.
- Ravančić DB, Pantović MM, Milovanović DR, Đukić-Dejanović S, Janjić V, Ignjatović DR et al. Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. *Psychiatria Danubina* 2009;21:179-186.
- Ray W, Chung C, Murray K, Hall K, Stein M. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. *N Engl J Med* 2009;360:225-235.
- Readler TJ, Knable MB, Lafargue T et al. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. *Psychiatr Res* 1999;90:81-90.
- Redmond C, Larkin M, Harrop C. The personal meaning of romantic relationships for young people with psychosis. *Clin Child Psychol Psychiatry* 2010;15:151-170.
- Reed R, Harrow M, Herbecer E, Martin E. Executive function in schizophrenia: is it linked to psychosis and poor life function? *J Nerv Ment Dis* 2002;190 (11):725-732.
- Reilly JG, Ayes SA, Ferrier IN. QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. *Lancet* 2000;335:1048-1052.
- Remington G, Chong SA, Kapur S. Distinguishing change in primary and secondary negative symptoms. *Am J Psychiatry* 1999;156(6):974-975.
- Remington GS, Kapur S. D2 and 5HT2 receptor effects on antipsychotics: Bridging basic and clinical findings using PET. *J Clin Psychiatry* 1999;60(Suppl10):15-19.
- Rey J. Cannabis and mental health. *Br Med J* 2002;325:1183-1184.
- Reznik I, Mester R. Genetic factors in clozapine-induced agranulocytosis. *Isr Med Assoc J* 2000;2:857-858.
- Ridgely MS, Goldman HH, Willenbring M. Barriers to the care of persons with dual diagnosis: organizational and financing issues. *Schizophr Bull* 1990;16:123-132.
- Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P et al. The Basel early-detection-of-psychosis (FEPsy)-study-design and preliminary results. *Acta Psychiatr Scand* 2007;115:114-125.
- Riecher-Rössler A, Rössler W, Förstl H, Meise U. Late-onset schizophrenia and late paraphrenia. *Schizophren Bulletin* 1995;21:345-354.
- Ritsner M. The attribution of somatization in schizophrenia patients: a naturalistic follow-up study. *J Clin Psychiatry* 2003;64(11):1370-1378.
- Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 1999;56:241-247.
- Robinson DG, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koren A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 1999;56(3):241-247.
- Robinson DG, Woerner MG, Alvir JM, Geisler S, Koren A, Sheitman B et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. *Am J Psychiatry* 1999;156:544-549.

- Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. *Schizophr Res* 2002;57(2-3):209-219.
- Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological Treatments for First-Episode Schizophrenia. *Schizophr Bull* 2005;31:705-722.
- Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2004;161(3):473-479.
- Robles García R, Salazar Alvarado V, Paez Agraz F, Ramírez Barreto F. Assessment of drug attitudes in patients with schizophrenia: psychometric properties of the DAI Spanish version. *Actas Esp Psiquiatr* 2004;32:138-142.
- Robles GR, Salazar AV, Páez AF, Ramírez BF. Evaluación de actitudes al medicamento en pacientes con esquizofrenia: propiedades psicométricas de la versión en español del DAI. *Actas Españolas Psiquiatría* 2004;32:138-142.
- Rocca P, Castagna F, Mongini T. Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia. *Psychiatry Res* 2010;177:71-76.
- Roder V, Mueller D, Mueser KT, Brenner H. Integrated psychological therapy (IPT) for schizophrenia. Is it effective? *Schizophr Bull* 2006;32:S1-S93.
- Rodríguez V MS, Brunner RE, Ortega-Soto HA. La percepción de los síntomas extrapiramidales por el paciente y sus familiares. Tesis de especialidad. Departamento de Psicología y Salud Mental, Facultad de medicina 1999;UNAM-IMP-4-24.
- Ronaldson K, Taylor A, Fitzgerald P, McNeil J. Diagnostic characteristics of clozapine-induced myocarditis identified by analysis of 38 cases and 47 controls. *J Clin Psychiatr* 2010;71(8):976-981.
- Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: Frequency, clinical presentation, and response to lorazepam. *J Clin Psychiatry* 1990;51:357-362.
- Rosen I. The clinical significance of obsessions in schizophrenia. *J Ment Sci* 1957;103:773-785.
- Rosenheck RA, Leslie DL, Doshi JA. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. *Psychiatr Serv* 2008;59:515-520.
- Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. *Am J Psychiatry*. 2006;163:2080-2089.
- Rosenthal D. Genetic theory and abnormal behavior. New York: McGraw Hill; 1970.
- Rossi A, Bustini M, Prosperini P, Marinangeli M, Splendiani A, Daneluzzo E, Stratta P. Neuromorphological abnormalities in schizophrenic patients with good and poor outcome. *A Psychiatric Scandinav* 2000;101(2):161-166.
- Rössler W, Salize HJ, Cucchiari G, Reinhard I, Kerning C. Does the place of treatment influence the quality of life of schizophrenics? *Acta Psychiatrica Scandinav* 1999;100(2):142-148.
- Roth BL, Craig SC, Choudhary MS. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. *J Pharmacol Exp Ther* 1992;268:1403-1410.
- Roth R, Flashman L, Saykin A, McAllister TH, Vidaver R. Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits. *Am J Psychiatry* 2004;161:157-159.
- Rousseau C. Playing around with a story. *Transcult Psychiatry* 1999;36(4):447-450.
- Rown S. Excess mortality of schizophrenia. A meta-analysis. *Br J Psychiatry* 1997;171:502-508.
- Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders. *Aust N Z J Psychiatry* 2005;39:1-30.
- Royal College of Psychiatrists. CR176. The ECT Handbook. (3rd. edition). London: RCPsych Publications.
- Rubinson EP, Asnis GM. Utilización de entrevistas estructuradas para el diagnóstico. En: Wetzler S (ed). *Medición de las enfermedades mentales: Evaluación psicométrica para los clínicos*. Ancora. Barcelona; 1991:41-63.
- Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. *Arch Gen Psychiatry* 2010;67:241-251.
- Rummel C, Hansen WP, Helbig A, Pitschel-Walz GP, Kissling W. Peer-to-peer psychoeducation in Schizophrenia: A new approach. *J Clin Psychiatry* 2005;66:1580-1585.
- Rummel-Kluge C, Kissling W. Psychoeducation in schizophrenia: new developments and approaches in the field. *Curr Opin Psychiatry* 2008;21:168-172.
- Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. *Schizophr Bull* 2012;38:167-177.
- Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2010;123:225-233.
- Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. *Psychopharmacology (Berl)* 1986;88:403-419.
- Ryan P. Un programa experimental psicosocial para pacientes agudos hospitalizados. I Reunión sobre Investigación y Enseñanza. Instituto Mexicano de Psiquiatría 1982;196-202.
- Ryan P, Valencia M, Otero BR, Núñez M, González N, Rascón ML. Alternativas para el hospitalismo. *Salud Mental* 1982;5(3):8-15.
- Sachdev P. The development of the concept of akathisia: A historical overview. *Schizophr Res* 1995;161:33-45.
- Sackeim HA. Central issues regarding the mechanisms of action of electroconvulsive therapy: Directions for future research. *Psychopharmacol Bull*. 1994;30(3):281-308.
- Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. *J Clin Psychopharmacol* 1990;10:96-104.
- Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry. 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007.
- Sainfort F, Becker M, Diamond R. Judgments of quality of life of individuals with severe mental disorders: patients self-report versus provider perspectives. *Am J Psychiatry* 1996;153:497-502.
- Sajatovic M, Meltzer HY. The effect of short-term electroconvulsive treatment plus neuroleptics in treatment resistant schizophrenia and schizoaffective disorder. *Convuls Ther* 1993;9:167-175.
- Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. *Ann Gen Psychiatry* 2005;4:1-6.
- Salgado-Pineda P, Caclin A, Baeza I, Junque C, Bernardo M, Blin O et al. Schizophrenia and frontal cortex: where does it fail? *Schizophr Res* 2007;91:73-81.
- Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE. Intermittent drug techniques for schizophrenia. *Cochrane Database Syst Rev* 2013 Jul 20;7:CD006196.
- Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. *CNS Drugs* 2011;25:829-845.
- Sanchez MA, Mares ML. Modelo de intervención multifamiliar y unifamiliar con pacientes esquizofrénicos. *Psicología Iberoamericana* 1998;6:34-39.
- Sandoz Pharmaceuticals Company. Clozaril (Clozapine) Treatment Trends 1995;4:1-4.
- Sarkar P, Andrade C, Kapur B, Das P, Sivaramakrishna Y, Harihar C et al. An exploratory evaluation of ECT in haloperidol-treated DSM-III-R schizophreniform disorder. *Convuls Ther* 1994;10:271-278.
- Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, Day R. Early manifestations and first-contact incidence of schizophrenia in different cultures. *Psychological Medicine* 1986;16:909-928.
- Saugstad LF. Are neurodegenerative disorder and psychotic manifestations avoidable brain dysfunctions with adequate dietary omega-3? *Nutr Health* 2006;18:203-215.
- Sawa A, Snyder SH. Schizophrenia. Diverse Approaches to a Complex Disease. *Science* 2002;296:692-695.
- Scott AIF. College guidelines on electroconvulsive therapy: an update for prescribers. *Adv Psychiatric Treat* 2005;11:150-156.
- Scharfetter C. Dissociation and schizophrenia. *Schizophrenias - a dissociative nosopoietic construct?* *Fortschr Neurol Psychiatr* 1998;66(11):520-523.
- Schmauss M, Sacchetti E, Kahn JP, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. *Int Clin Psychopharmacol* 2007;22:85-92.
- Schooler E, Caudill W. Symptomatology in Japanese and American schizophrenics. *Ethnology* 1964;3:172-178.
- Schooler N, Keith S, Severe J, Matthews S, Bellack A, Glick I et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. *Arch Gen Psychiatry* 1997;54:453-463.
- Schooler N. Relapse Prevention and Recovery in the Treatment of Schizophrenia. *J Clin Psychiatry* 2006;67:19-23.
- Schreier A, Wolke D, Thomas K. Prospective study of peer victimization in childhood and psychotic symptoms in a non clinical population at age 12 years. *Arch Gen Psychiatry* 2009;66:527-536.
- Schultze-Lutter F, Ruhrmann S, Hoyer C, Klosterkötter J, Leweke FM. The initial prodrome of schizophrenia: different duration, different underlying deficits? *Compr Psychiatry* 2007;48:479-488.
- Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. *Cochrane Database Syst Rev*. 2008 Jul 16;(3):CD004028. Doi:10.1002/14651858.CD004028.pub3.
- Sciarretta A, Piazzi G. Long-term safety of ziprasidone in schizophrenic patients: an open trial. *Eur Rev Med Pharmacol Sci* 2012;16:2113-2119.
- Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. *Nature* 1976;261:717-719.
- Seeman P. Atypical Antipsychotics: Mechanism of Action. *Can J Psychiatr* 2002;47:27-38.
- Sellwood W, Barrowclough C, Tarrier N, Quinn J, Mainwaring J, Lewis S. Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. *Acta Psychiatr Scand* 2001;104:346-355.
- Sendi PP, Craig BA, Pfluger D, Gafni A, Bucher HC. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. *J Eval Clin Pract* 1999;5:283-295.
- Sepúlveda J, Torres RR. Experiencias de Psiquiatría comunitaria en Chile. Monografía del Curso de Gestión en Psiquiatría y salud mental. Dirección de Posgrado de la Universidad de Santiago de Chile; 2001.
- Shaner A, Eckman T, Roberts LJ, Fuller T. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. *Psychiatr Serv* 2003;54:1287-1289.
- Sharma ND, Rosmann HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. *Am J Cardiol* 1998;81:238-240.
- Shean G. Evidence-Based Psychosocial Practices and Recovery from Schizophrenia. *Psychiatry* 2009;72:307-320.
- Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. *J Psychiatr Research* 1998;32, 143-150.

- Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. *Schizophrenia Res* 2001;49:1-52.
- Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. *Psychol Med Monogr* 1989;15(Suppl):1-46.
- Shern D, Tsemberis S, Anthony W, Novell A, Richmond L, Felton Ch, Winarski J, Cohen M. Serving street-dwelling individuals with psychiatric disabilities: outcomes of a psychiatric rehabilitation clinical trial. *Am J Public Health* 2000;90:1873-1878.
- Shim G, Kang DH, Choi JS, Jung MH, Kwon SJ, Jang GE et al. Prospective outcome of early intervention for individuals at ultra-high-risk for psychosis. *Early Interv Psychiatry* 2008;2:277-284.
- Siever L, Davis K. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. *Am J Psychiatry* 2004;161:398-413.
- SIGN. Scottish Intercollegiate Guidelines Network (SIGN) 2008.
- Silver H, Feldman P, Bilker W, Gur R. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. *Am J Psychiatry* 2003;160:1809-1816.
- Singh V, Vijapurkar U, Robb A. Efficacy, safety and tolerability of paliperidone ER in adolescent patients with schizophrenia. Poster presented at: 65th Annual Meeting of the Society of Biological Psychiatry. New Orleans, LA. May 20-22, 2010.
- Sipos A, Rasmussen F, Harrison G, Tynelius P, Lewis G, Leon DA et al. Paternal age and schizophrenia: a population based cohort study. *BMJ* 2004;32:1070-1075.
- Siris SG, Addington D, Azorin JM, Falloon IR, Gerlach J, Hirsch SR. Depression in schizophrenia: recognition and management in the USA. *Schizophr Res* 2001;47:185-197.
- Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. *Eur J Pharmacol* 1995;281:289-294.
- Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH et al. Electroconvulsive treatment compared with lithium in the management of manic states. *Arch Gen Psychiatry* 1988;45:727-732.
- Small JG. Efficacy of electroconvulsive therapy in schizophrenia, mania and other disorders. *1 Schizophrenia. Convulsive Ther* 1985;1:263-270.
- Smith ML, Gene V, Miller, TI. The Benefits of Psychotherapy. The Johns Hopkins University Press 1980.
- Sociedad Española de Psiquiatría. Consejo español sobre la terapia electroconvulsiva (TEC) 1999.
- Solomon P, Draine J, Mannion E, Meisel M. Increased contact with community mental health resources as a potential benefit of family education. *Psychiatr Serv* 1998;49:333-339.
- Sommer I, Ramsey N, Kahn R, Aleman A, Bouma A. Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. *Br J Psychiatry* 2001;178:344-351.
- Sorensen SV. Technical appendix for "The health and economic benefits of treating schizophrenia model". Technical Appendix prepared for Pfizer. MEDTAP International 2003;A2:1875.
- Sota S, Shimodera S, Kii M, Okamura K, Suto K, Suwaki M et al. Effect of a family psychoeducational program on relatives of schizophrenia patients. *Psychiatry Clin Neurosci* 2008;62:379-385.
- Soyka M, Wegner U, Moeller HJ. Risperidone in treatment-refractory chronic alcohol hallucinosis. *Pharmacopsychiatry* 1997;30:135-136.
- Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. *J Clin Psychiatry* 1997;58:318-322.
- Sramek JJ, Mack RJ, Awani W, Hourani J, Jhee SS, Barto S et al. Two rapid-dose titrations of sertindole in patients with schizophrenia. *J Clin Psychopharmacol* 1997;17:419-422.
- Stahl SM, Morrisette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM et al. Meta-guidelines for the management of patients with schizophrenia. *CNS Spectr* 2013;18:150-162.
- Stanford AD, Sharif Z, Corcoran C, Urban N, Malaspina D, Lisanby SH. rTMS strategies for the study and treatment of schizophrenia: a review. *Int J Neuropsychopharmacol* 2008;11:563-576.
- Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. *Aust N Z J Psychiatry* 2012;46:816-825.
- Stip E, Abdel-Baki A, Bloom D, Grignon S, Roy MA. Long-acting injectable antipsychotics: an expert opinion from the Association des medecins psychiatres du Quebec. *Can J Psychiatry* 2011;56:367-376.
- Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. *Int Clin Psychopharmacology* 2005;20:243-251.
- Straub RE, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. *Nat Genet* 1995;11:287-293.
- Strauss ME, Buchanan RW, Hale J. Relations between attentional deficits and clinical symptoms in schizophrenic outpatients. *Psychiatry Res* 1993;47:205-213.
- Stroup TS, Geddes JR. Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. *Schizophr Bull* 2008;34:266-274.
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006;163:611-622.
- Stroup TS, Lieberman JA, McEvoy JP. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. *Am J Psychiatry* 2007;164:415-427.
- Susser E, Neugebauer R, Hoek HW, Brown AS, Lin S, Labovitz D et al. Schizophrenia after prenatal famine. *Arch Gen Psychiatry* 1996;53:25-31.
- Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. *Drugs* 2004;64:1715-1736.
- Swank M, Dixon L. Family psychoeducation as an evidence-base practice. *CNS Spectr* 2004;9:905-912.
- Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS et al. What CATIE found: results from the schizophrenia trial. *Psychiatr Serv* 2008;59:500-506.
- Sweeney JA, Haas GL, Keilp JG, Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study. *Psychiatry Res* 1991;38:63-76.
- Swerdlow NR. Are we studying and treating schizophrenia correctly?. *Schizophr Res* 2011;130:1-10.
- Szmukler G, Herrman H, Colusa S, Benson A, Bloch S. A controlled trial of a counseling intervention for caregivers of relatives with schizophrenia. *Soc Psychiatry Psychiatr Epidemiol* 1996;31:149-155.
- Szmukler Gi, Burgers P. Caring for relatives with serious mental illness: The Experiences of caregiving inventory. *Soc Psychiatry Psychiatr Epidemiol* 1996;31:137-148.
- Tai S, Turkington D. The evolution of cognitive behavior therapy for schizophrenia: Current practice and recent developments. *Schizophr Bull* 2009;35:865-873.
- Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. *Schizophr Res* 2012;134:219-225.
- Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. *Schizophr Res* 2009;110:1-23.
- Tandon R, Nasrallah HA. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses. *Arch Gen Psychiatry* 2006;63:935-937.
- Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. *J Clin Psychiatry* 2011;72:4-8.
- Tandon R. The Nosology of Schizophrenia: Toward DSM-5 and ICD-11. *Psychiatr Clin N Am* 2012;35:557-569.
- Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. *J Med Toxicol* 2008;4:101-105.
- Tarrier N, Barrowclough C, Vaughn C, Bamrah JS, Porceddu K, Watts W et al. The community management of schizophrenia: A controlled trial of a behavioural intervention with families to reduce relapse. *Br J Psychiatry* 1988;153:532-542.
- Tarrier N, Barrowclough C. Family intervention in schizophrenia and their long-term outcomes. *Internat J Ment Health* 1995;24:38-53.
- Tarrier N, Haddock G, Barrowclough C. Training and dissemination: Research to practice in innovative psychosocial treatments for schizophrenia. Cap. 12. In: Wylkes T, Tarrier N, Lewis S (eds). Outcome and innovation in psychological treatment of schizophrenia. John Wiley & Sons; 1998.
- Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. *Clin Neuropharmacol* 1983;6:59-526.
- Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. *Br J Psychiatry* 2009;52(Suppl):S13-S19.
- Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. *Cochrane Database Syst Rev* 2005 Apr 18;(2):CD000076.
- Thirithalli J, Vivek H, Muralidharan K, Channaveerachari NK, Bharat M, Prashant B et al. Does catatonic schizophrenia improve faster with electroconvulsive therapy than other subtypes of schizophrenia? *W J Biol Psychiatry* 2009;10:772-777.
- Thomas H, Dalman C, David A, Gentz J, Lewis G, Allebeck P. Obstetric complications and risk of schizophrenia. Effect of gender, age at diagnosis and maternal history of psychosis. *Br J Psychiatry* 2001;179:409-414.
- Thornicroft G, Stathdee G, Phelan M. Rationale and design: PRISM psychosis study I. *Br J Psychiatry* 1998;173:363-370.
- Thornicroft G, Susser E. Evidence-based psychotherapeutic interventions in the community care of schizophrenia. *Br J Psychiatry* 2001;176:2-4.
- Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G et al. Integrated treatment ameliorates negative symptoms in first episode psychosis-results from the Danish OPUS trial. *Schizophr Res* 2005;79:95-105.
- Tibbo P, Warneke L. Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. *J Psychiatry Neurosci* 1999;24:15-24.
- Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Am J Psychiatry* 2011;168:603-609.
- Tiihonen J, Lönnqvist J, Wahlbeck K. 11-year follow-up of mortality in patient with schizophrenia: a population-based cohort study (FIN1 study). *Lancet* 2009;374:620-627.
- Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 2006;333:224.
- Tohen M, Strakowski SM, Zarate C Jr, Hennen J, Stoll AL, Suppes T et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. *Biol Psychiatry* 2000;48:467-476.
- Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative. *Am J Psychiatry* 1997;154:457-465.

- Toren P, Tatner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. *Drug Saf* 2004;27:1155-1156.
- Torrey EF, Torrey BB, Burton-Bradley BG. The epidemiology of schizophrenia in Papua New Guinea. *Am J Psychiatry* 1974;131:576-578.
- Trainor JN, Morell-Bellai TL, Ballantyne R, Boydell KM. Housing for people with mental illnesses: a comparison of models and an examination of the growth of alternating housing in Canada. *J Clin Psychiatry* 1997;58:494-501.
- Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. *J Clin Psychiatry* 1997;58:205-211.
- Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CM. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:407-418.
- Tsang WH. Social skills training to help mentally ill persons find and keep a job. *Psychiatr Serv* 2001;52:891-894.
- Tsuang J, Fong TW. Treatment of patients with schizophrenia and substance abuse disorders. *Curr Pharm Des* 2004;10:2249-2261.
- Tsuang M, Stone W, Faraone S. Genes, environment and schizophrenia. *Br J Psychiatry* 2001;178:18-24.
- Tumkaya S, Karadag F, Oguzhanoglu NK, Tekkanat C, Varma G, Ozdel O et al. Schizophrenia with obsessive-compulsive disorder and obsessive-compulsive disorder with poor insight: a neuropsychological comparison. *Psychiatry Res* 2009;165:38-46.
- Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. *Br J Psychiatry* 2002;180:523-527.
- Turkington D, Morrison AP. Cognitive Therapy for Negative Symptoms of Schizophrenia. *Arch Gen Psychiatry* 2012;69:119-120.
- Twamley E, Jeste D, Lehman A. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. *J Nerv Ment Dis* 2003;191:515-523.
- Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. *J Clin Psychopharmacol* 2011;31:497-502.
- Uçok A, Cakr S. Electroconvulsive therapy in first-episode schizophrenia. *J ECT* 2006;22:38-42.
- Uribe CA. El ritual y la "locura": Psiquiatría y cultura en Colombia. *Rev Col Psiquiatría* 1998;27:40.
- Uribe CA. La controversia por la cultura en el DSM-IV. *Rev Col Psiquiatría* 2000;29:345-365.
- Uzun O, Cansever A, Basoglu C, Ozsahin A. Smoking and substance abuse in outpatients with schizophrenia: a 2-year follow-up study in Turkey. *Drug Alcohol Depend* 2003;70:187-192.
- Vahia IV, Palmer BW, Depp C, Fellows I, Golshan S, Kraemer HC et al. Is late-onset schizophrenia a subtype of schizophrenia? *Acta Psychiatrica Scand* 2010;224:414-426.
- Valencia CM. Trastornos mentales y problemas de salud mental: Día mundial de la salud mental 2007. *Salud Mental* 2007;30:75-80.
- Valencia M, Diaz A, Juárez F. Integration of pharmacological and psychosocial treatment for schizophrenia: the case of a developing country proposal. En: Zhu H, Markowitz JS (eds). *Pharmacotherapy*. InTech Publishers (En Prensa); 2012.
- Valencia M, Lara MC, Rascón ML, Ortega H. La importancia de los tratamientos farmacológico y psicosocial de los pacientes con esquizofrenia. *Rev Latinoam Psiquiat* 2002;2:6-21.
- Valencia M, Liberman RP, Rascón ML, Juárez F. Capítulo 1. Habilidades psicosociales para la esquizofrenia. En: Valencia M (Compilador). *Alternativas terapéuticas para la esquizofrenia*. Editorial Herder (En Prensa); 2012.
- Valencia M, Ortega H, Rascón ML, Gómez L. Evaluación de la combinación de los tratamientos psicosocial y farmacológico en pacientes con esquizofrenia. *Actas Espan Psiquiat* 2002;30:358-369.
- Valencia M, Ortega H. El tratamiento psicosocial en los pacientes con esquizofrenia. En: Ortega H, Valencia M (eds). *Esquizofrenia: Estado Actual y Perspectivas*. Colección de libros del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, México, D.F. 2001;399-454.
- Valencia M, Ortega-Soto H, Rodríguez M, Gómez L. Estudio comparativo de consideraciones clínicas y psicoterapéuticas en el tratamiento biopsicosocial de la esquizofrenia. Primera parte. *Salud Mental* 2004;27:47-53.
- Valencia M, Otero BR, Rascón ML. Un modelo de intervención clínica en un hospital mental. *Acta Psiquiatr Psicol Am Lat* 1986;32:41-51.
- Valencia M, Rascón ML, Juárez F, Escamilla R, Saracco R, Liberman RP. Application in Mexico of psychosocial rehabilitation with schizophrenia patients. *Psychiatry* 2010;73:248-263.
- Valencia M, Rascón ML, Juárez F, Muro E. A psychosocial skills training approach in Mexican out-patients with schizophrenia. *Psychol Med* 2007;37:1393-1402.
- Valencia M, Rascón ML, Otero R, Ryan P. Descripción de la conducta de pacientes Psiquiátricos hospitalizados. *Salud mental* 1987;10:81-89.
- Valencia M, Rascón ML, Quiroga H. Aportaciones de la investigación respecto al tratamiento psicosocial y familiar de pacientes con esquizofrenia. *Salud mental* 2003;26:1-18.
- Valencia M, Rascón ML. Abordaje psicoterapéutico de la esquizofrenia en pacientes agudos y crónicos. *Rev Iberoamericana Psicol* 1998;8:18-33.
- Valencia M, Rojas E, González C, Ramos L, Villatoro J. Evaluación del funcionamiento psicosocial en pacientes de un centro de salud. *Rev Sal Púb Méx* 1989;31:674-687.
- Valencia M, Saldivar H, Rivera G. 18-month follow-up of patients with schizophrenia. *Salud Pública Mex* 1994;36:662-669.
- Valencia M. El hospital mental como instrumento terapéutico: El rol del psicólogo en la práctica clínica institucional. *Rev Mex Psicol* 1991;8:99-107.
- Valencia M. El manejo comunitario de la esquizofrenia. En: Ortega H, Valencia M (eds). *Esquizofrenia: Estado actual y perspectivas*. Colección de libros del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, México, D.F. 2001;547-607.
- Valencia M. Formulación de principios de tratamiento y rehabilitación del paciente psicótico. *Rev Mex Psicol* 1986;3:37-43.
- Valencia M. Funcionamiento psicosocial en pacientes con esquizofrenia: treinta meses de seguimiento comunitario. *Rev Salud Mental* 1997;20:28-37.
- Valencia M. Manejo psicosocial del paciente esquizofrénico. *Rev Psiquiatría* 1996;12:72-86.
- Valencia M. Programa de intervención psicosocial para pacientes esquizofrénicos crónicos. *Rev Salud Mental* 1999;22:128-137.
- Valencia M. Tratamiento psicosocial en pacientes esquizofrénicos del Instituto Mexicano de Psiquiatría. *Salud Mental* 1999;2:31-40.
- Valencia M. Un programa de tratamiento psicosocial para pacientes psicóticos agudos. *Rev Psiquiatría* 1988;12:72-86.
- Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. *Schizophr Bull* 2004;30:255-264.
- Valenstein M, Copeland LA, Owen R et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. *J Clin Psychiatry* 2001;62:545-561.
- Vallina FO, Lemos GS. Dos décadas de intervenciones familiares en la esquizofrenia. *Psicothema* 2000;12:671-681.
- Van den Anker JN. Developmental pharmacology. *Dev Dis Res Rev*. 2010;16:233-238.
- Van der Stelt O, Frye J, Lieberman J, Belger A. Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. *Arch Gen Psychiatry* 2004;61:237-248.
- Van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. *BMJ* 1999;319:623-626.
- Van Noord C, Straus S, Sturkenboom M, Hofman A, Aarnoudse AJ, Bagnardi V et al. Psychotropic drugs associated with corrected QT interval prolongation. *J Clin Psychopharmacology* 2009;29:9-15.
- Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. *Am J Epidemiol* 2002;156:319-327.
- Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. *Arch Gen Psychiatry* 1981;38:187-190.
- Varma VK. Transcultural perspective on schizophrenia: Epidemiology, manifestations and outcome. *Transcultural Psychiatry Section. World Psychiat Assoc* 2000;18(1).
- Vaughn C, Doyle M, McConaghy N, Blascynski A, Fox A, Tarrier N. The Sidney intervention trial: A controlled trial of relatives counselling to reduce schizophrenic relapse. *Soc Psychiatry Psychiatr Epidemiol* 1992;27:16-21.
- Vaughn CE, Snyder KS, Jones S, Freeman WB, Faloon IR. Family Factors In Schizophrenic Relapse: Replication In California of British Research in E.E. *Arch Gen Psychiatry* 1984;41:1169-1177.
- Vázquez B, Herrero CS, Gaité L. La entrevista estructurada en Psiquiatría. *Rev. Asoc. Esp. Neuropsiq* 1993;13:29-37.
- Vella D. Comorbidity in Psychiatry. *Psychopathol* 2000;1:46-52.
- Velligan DI, Kern R, Gold JM. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. *Schizophr Bull* 2006;32:474-485.
- Velthorst E, Nieman DH, Becker HE, van de Fliet R, Dingemans PM, Klaassen R et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. *Schizophr Res* 2009;109:60-65.
- Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. *Acta Psychiatr Scand* 2000;102:203-210.
- Verduzco FW, Escobedo IO, Anaya GP. Estudio de costos de hospitalización por Esquizofrenia. Instituto Mexicano del Seguro Social, citado Mar 2006. Disponible en: www.imss.gob.mx
- Veser FH, Vesper BD, McMullan JT, Zealberg J, Currier GW. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. *J Psychiatr Pract* 2006;12:103-108.
- Vesterager L, Christensen T, Olsen BB, Kraup G, Forchhammer HB, Melau M et al. Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): A study protocol for a centrally randomized, observer-blinded multicentre clinical trial. *Bio Med Central* 2011;12:1-9.
- Viesca-Treviño C. Usos de las plantas medicinales mexicanas. *Arqueología mexicana*, 1999;7:30-35.
- Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. *Drugs Aging* 2009;26:997-1012.
- Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. *Psychosomatics* 2004;45:371-377.
- Villamil SV, Estrada GJ, López FM. Experiencia de un modelo de atención primaria en salud mental (Fase piloto) *Psiquiatría* 2006;22:7-12.
- Villamil SV, Valencia CM, Diaz ML, Medina M, Juárez F. Funcionamiento psicosocial de pacientes esquizofrénicos de acuerdo con su consumo de alcohol. *Salud Mental* 2005;28:40-48.
- Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. *Prog Neuro Psychopharmacol Biol Psychiatry* 2008;32:405-413.

- Villaseñor Bayardo SJ, Baena Zúñiga A, Virgen Montelongo R, Aceves Pulido MP, Moreno M, González IP. La participación de la familia del paciente en la hospitalización psiquiátrica de "Puertas Abiertas". Un modelo de atención etnopsiquiátrica. *Rev Neuro Psiquiatr* 2003;66:185-194.
- Villaseñor-Bayardo SJ. L'elaboration du concept de bouffée délirante. *Mémoire EHESS*. Paris. 1992; p.95.
- Villaseñor-Bayardo SJ, Díaz-Martínez A. Observaciones etnopsiquiátricas Nahuas. *Psiquiatría* 1995;11:1-5.
- Villaseñor-Bayardo SJ. De la variabilidad nosológica: el caso de los Nahuas de Guerrero en México. *Inv Salud* 1999;1:87-93.
- Villaseñor-Bayardo SJ. El concepto de la "bouffée délirante" dentro de las clasificaciones de las enfermedades mentales. *Rev Res Psiquiat* 1993;4:26-30.
- Villaseñor-Bayardo SJ. La etnopsiquiatría. Nociones generales sobre su origen y desarrollo. *Salud Mental* 1994;17:16-20.
- Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J et al. Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients with Chronic Schizophrenia and Schizoaffective Disorder. *Am J Psychiatry* 2002;159:255-262.
- Volkow ND, Fowler JS. Neuropsychiatric disorders: investigation of schizophrenia and substance abuse. *Semin Nucl Med* 1992;22:254-267.
- Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. *Ment Retard Dev Disabil Res Rev* 2001;7:56-64.
- Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. *Cochrane Database Syst Rev* 2007;Jan 24;(1):CD006391.
- Von Knorring L, Lindstrom E. Principal components and further possibilities with the PANSS. *Acta Psychiatr Scand* 1995;388(Suppl):5-10.
- Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. *Cochrane Database Syst Rev* 2000;(2):CD000059.
- Wahlbeck K, Osmond C, Forsén T, Barrer D, Ericsson J. Associations between childhood living circumstances and schizophrenia: a population-based cohort study. *Acta Psychiatr Scand* 2001;104:356-360.
- Waish E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. *Br J Psychiatry* 2001;180:490-495.
- Walker E, Kestler L, Bollini A, Hochman K. Schizophrenia: etiology and course. *Annu Rev Psicol* 2004;55:401-430.
- Wallace C, Mullen P, Burgess P, Palmer S, Ruschena D, Browne C. Serious criminal offending and mental disorder. Case linkage study. *Br J Psychiatry* 1998;172:477-484.
- Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. *N Engl J Med* 2005;353:2335-2341.
- Watts FN, Bennett DH. Rehabilitación Psiquiátrica. Teoría y práctica. Compilación a cargo de Ed. Noriega Limusa 1990.
- Wehmeier P, Kluge M, Schacht A. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. *J Psychiatric Res* 2008;42:676-683.
- Weiden PJ, Olsson M. Cost of relapse in schizophrenia. *Schizophr Bull* 1995;21:419-429.
- Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? *Arch Gen Psychiatry* 2002;59:553-558.
- Weinberger DR. From neuropathology to neurodevelopment. *Lancet* 1995;348:552-557.
- Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. *Arch Gen Psychiatry* 1987;44:660-667.
- Weiner RD, Coffey CE, Krystal AD. The monitoring and management of electrically induced seizures. *Psychiatr Clin N Am* 1991;14:845-869.
- Weiner RD, Coffey CE. Indications for use of electroconvulsive therapy. En: Frances AJ, Hales RE (eds). *Review of Psychiatry Volume 7*. Washington, DC: American Psychiatric Press, Inc. 1988;458-481.
- Weiner RD, Rogers HJ, Davidson JR, Khan EM. Effects of electroconvulsive therapy upon brain electrical activity. *Ann NY Acad Sci* 1986;462:270-281.
- Weiner RD. The role of stimulus waveform in therapeutic and adverse effects of ECT. *Psychopharmacol Bull* 1982;18:71-72.
- Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: Systematic review. *Schizophr Res* 2009;113:1-11.
- Weisman de Mamani A, Wasserman S, Duarte E, Dunham R, Koneru V. Capítulo 5. Un tratamiento familiar para esquizofrenia basado en la información cultural. En: Valencia M. *Alternativas terapéuticas para la esquizofrenia*. Editorial Herder. México 2012.
- Weiss F, Danzl C, Hummer K, Kemmler G, Lindner C, Reinstadler K et al. Weight gain induced by olanzapine. *Schizophr Res* 1998;29:179.
- Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. *Pharmacopsychiatry* 2010;43:279-281.
- Werner A. Obsessive-compulsive symptoms in schizophrenia. *Am J Psychiatry* 1997;154:1635-1636.
- Werry JS, McClellan JM, Andrews LK, Ham M. Clinical features and outcome of child and adolescent schizophrenia. *Schizophr Bull* 1994;20:619-630.
- Whitney KA, Fastenau PS, Evans JD, Lysaker PH. Comparative neuropsychological function in obsessive-compulsive disorder and schizophrenia with and without obsessive-compulsive symptoms. *Schizophr Res* 2004;69:75-83.
- Whittington C, Barnes TRE, Kendall T. Antipsychotics for people with persistent negative symptoms of schizophrenia. *Cochrane Database of Systematic Reviews* 2010.
- WHO heads of Centres Collaborating in WHO Co-Ordinated Studies on Biological Aspects of Mental Illness. Prophylactic Use of Anticholinergics in Patients on Long-Term Neuroleptic Treatment. *Br J Psychiatry* 1990;156:412.
- WHO. The World Health Report. Life in the 21st Century: A vision for all. Geneva: WHO; 1998.
- Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. *Schizophr Bull* 1998;24:75-85.
- Wiersma D, Wanderling J, Dragomirecka E, Ganey K, Harrison G, Der Heiden W et al. Social disability in schizophrenia: its developmental and prediction over 15 years in incident cohorts in six European centres. *Psychol Med* 2000;30:1155-1167.
- Wig NN. Diagnóstico y clasificación en psiquiatría. Aspectos transculturales. *Confrontaciones psiquiátricas* 1984;20:12-45.
- Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature* 1995;376:572-575.
- Wing JK, Brown GW. Institutionalism and schizophrenia. Cambridge University Press. London; 1970.
- Wittkower ED, Rin H. Transcultural psychiatry. *Arch Gen Psychiatry* 1965;13:387-394.
- Wittkower ED. Transcultural Psychiatry. In: John G Howells (ed). *Modern Perspectives in World Psychiatry*. New York: Blunner/Mazel; 1971.
- Wojtecki L, Colosimo C, Fuentes R. Deep brain stimulation for movement disorders - a history of success and challenges to conquer. *Front Integr Neurosci* 2012;6:6.
- Woodruff PW, McManus IC, David AS. Meta-analysis of corpus callosum size in schizophrenia. *J Neurol Neurosurg Psychiatry* 1995;58:457-461.
- Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. *Schizophr Bull* 2009;35:894-908.
- Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. *J Clin Psychiatry* 2010;71:463-474.
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J Clin Psychiatry* 2003;64:663-667.
- World Health Organization. International statistical classification of diseases and related health problems. 10th revision, 2nd ed. Geneva 2004.
- Worrel JA. Atypical antipsychotic agents: a critical review. *Am J Health Syst Pharm* 2000;57:238-255.
- Wright EC. Non-compliance-or how many aunts has Matilda? *Lancet* 1993;342:909-913.
- Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. *Am J Psychiatry* 2000;157:16-25.
- Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. *Am J Psychiatry* 2001;158:1149-1151.
- Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. *Clin Ther* 2003;25:1420-1428.
- Wu SY, Liu CC, Hsieh MH. Successful re-exposure to clozapine following uneventful re-challenge with olanzapine in a patient with neutropenia related to both agents. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:1089-1090.
- Wykes T, Tarrier N, Lewies S. Outcome and innovation in psychological treatment of schizophrenia. Wiley & Sons. Chichester; 1998.
- Wysokinski A, Kowman M, Kloszewska I. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review. *Psychiatr Danub* 2012;24:314-322.
- Xia J, Merinder L, Belgamwar MR. Psychoeducation for schizophrenia. *Schizophr Bull* 2011;37:21-22.
- Yamaguchi H, Takahashi A, Takano A, Kojima T. Direct effects of short-term psychoeducational intervention for relatives of patients with schizophrenia in Japan. *Psychiatry Clin Neurosci* 2006;60:590-597.
- Young A, Sullivan G, Burnam A. Measuring the quality of outpatient treatment for schizophrenia. *Arch Gen Psychiatry* 1998;55:611-617.
- Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. *Schizophrenia Bull* 1998;24:381-390.
- Yovell Y, Opler LA. Clozapine reverse cocaine craving in a treatment resistant mentally ill chemical abuse: a case report and a hypothesis. *J Nerv Ment Dis* 1994;182:591-592.
- Yung AR, Buckley JA, Cosgrave EM, Killackey EJ, Baker K, Cotton SM et al. Association between psychotic experiences and depression in a clinical sample over 6 months. *Schizophr Res* 2007;91:246-253.
- Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. *Schizophr Bull* 1996;22:283-303.
- Yung AR, McGorry PD. The prodromal phase of first episode psychosis: past and current conceptualizations. *Schizophr Bull* 1996;22:353-370.
- Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. *Aust N Z J Psychiatry* 1996;30:587-599.
- Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. *Schizophr Res* 2008;105:10-17.
- Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res* 2004;67:131-142.
- Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. *Schizophr Res* 2006;84:57-66.
- Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. *Br Med J* 2002;325:1199-1201.

- Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: a review from a clinical perspective. *W J Biol Psychiatry* 2012;13:96-105.
- Zhornitsky S, Stip E. Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. *Schizophr Res Treat* 2012;2012:407171. Doi:10.1155/2012/407171.
- Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AL. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorders: a retrospective survey. *J Clin Psychopharmacol* 2000;20:94-98.
- Zohar J, Kaplan Z, Benjamin J. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. *J Clin Psychiatry* 1993;54:385-388.
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J Clin Psychiatry* 2003; 64: 663-667.
- World Health Organization. International statistical classification of diseases and related health problems. 10th revision, 2nd ed. ed. Geneva 2004.
- Worrel JA. Atypical antipsychotic agents: a critical review. *Am J Health Syst Pharm* 2000; 57: 238-255.
- Wright EC. Non-compliance or how many aunts has Matilda? *Lancet* 1993; 342: 909-913.
- Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET: Meta-analysis of regional brain volumes in schizophrenia. *Am J Psychiatry* 2000; 157: 16-25.
- Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. *Am J Psychiatry* 2001; 158: 1149-1151.
- Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. *Clin Ther* 2003; 25: 1420-1428.
- Wu SY, Liu CC, Hsieh MH. Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32: 1089-1090.
- Wykes T, Tarrier N, Lewies S. Outcome and innovation in psychological treatment of schizophrenia. Wiley & Sons. Chichester; 1998.
- Wysokiński A, Kowman M, Kloszewska I. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review. *Psychiatr Danub* 2012; 24: 314-322.
- Xia J, Merinder L, Belgamwar MR. Psychoeducation for schizophrenia. *Schizophr Bull* 2011; 37: 21-22.
- Yamaguchi H, Takahashi A, Takano A, Kojima T. Direct effects of short-term psychoeducational intervention for relatives of patients with schizophrenia in Japan. *Psychiatry Clin Neurosci* 2006; 60: 590-597.
- Young A, Sullivan G, Burnam A. Measuring the quality of outpatient treatment for schizophrenia. *Arch Gen Psychiatry* 1998; 55: 611-617.
- Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine Schizophrenia Bull 1998; 24: 381-390.
- Yovell Y, Opler LA. Clozapine reverse cocaine craving in a treatment resistant mentally ill chemical abuse: a case report and a hypothesis. *J Nerv Ment Dis* 1994; 182: 591-592.
- Yung AR, Buckby JA, Cosgrave EM, Killackey EJ, Baker K, Cotton SM, et al. Association between psychotic experiences and depression in a clinical sample over 6 months. *Schizophr Res* 2007; 91: 246-253.
- Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. *Schizophr Bull* 1996; 22: 283-303.
- Yung AR, McGorry PD: The prodromal phase of first episode psychosis: past and current conceptualizations. *Schizophr Bull* 1996; 22: 353-370.
- Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. *Aust N Z J Psychiatry* 1996; 30: 587-599.
- Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. *Schizophr Res* 2008; 105: 10-17.
- Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res* 2004; 67: 131-42.
- Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. *Schizophr Res* 2006; 84: 57-66.
- Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. *Br Med J* 2002; 325: 1199-1201.
- Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: a review from a clinical perspective. *W J Biol Psychiatry* 2012; 13: 96-105.
- Zhornitsky S, Stip E. Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. *Schizophr Res Treat* 2012; 2012: 407171.
- Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AL. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorders: a retrospective survey. *J Clin Psychopharmacol* 2000; 20: 94-98.
- Zohar J, Kaplan Z, Benjamin J. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. *J Clin Psychiatry* 1993; 54: 385-388.